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Abstract: A novel rat model for a well-characterized human mitochondrial
disease, mitochondrial DNA depletion syndrome with associated
deoxyguanosine kinase (DGUOK) deficiency, is described. The rat model
recapitulates the pathologic and biochemical signatures of the human disease.
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The application of electron paramagnetic (spin) resonance (EPR) spectroscopy
to the identification and characterization of respiratory chain abnormalities in
the mitochondria from freshly frozen tissue of the mitochondrial disease
model rat is introduced. EPR is shown to be a sensitive technique for
detecting mitochondrial functional abnormality in situ and, here, is particularly
useful in characterizing the redox state changes and oxidative stress that can
result from depressed expression and/or diminished specific activity of the
distinct respiratory chain complexes. As EPR requires no sample preparation
or non-physiological reagents, it provides information on the status of the
mitochondrion as it was in the functioning state. On its own, this information
is of use in identifying respiratory chain dysfunction; in conjunction with other
techniques, the information from EPR shows how the respiratory chain is
affected at the molecular level by the dysfunction. It is proposed that EPR has
a role in mechanistic pathophysiological studies of mitochondrial disease and
strong potential as an additional diagnostic tool.
Keywords: DGUOK, redox, oxidative, stress, mtDNA depletion, pathology
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Introduction
Mitochondrial disease (MD) occurs where depletion of
mitochondrial DNA (mtDNA) or mutations in mtDNA and/or nuclear
DNA (nDNA) lead to altered mitochondrial function.1–4 Altered activities
of Complexes I – V have been identified and physiological
consequences of mitochondrial respiratory chain defects include
reduced metabolic capacity, reduced ATP synthesis, and increased
oxidative and nitrosative stress.5–15 Symptoms of MD are manifold and
include weakness (from central nervous system, peripheral nerve,
and/or skeletal muscle disease), pain, intolerance of some general
anesthetics and anti-epileptic drugs, gastrointestinal disorders,
ophthalmoplegia and/or visual failure, failure to thrive, cardiac and
respiratory disease, liver disease, diabetes, seizures, sensorineural
hearing loss, mental retardation, dementia, movement disorders,
increased susceptibility to infection, and pregnancy loss.1,2,16–38
Establishing diagnoses and understanding the pathophysiology of
mitochondrial disease (MD) has proven extremely challenging because
of the extraordinary range of clinical symptoms and testing
abnormalities.39 MD is often suspected in early childhood from clinical
differential diagnosis of patients with diseases involving the brain,
muscle, or liver. Traditional methods for diagnosing MD include clinical
presentation, family history, pathology, metabolic profiling, enzyme
activity levels, electrophysiology, magnetic resonance imaging (MRI)
of brain and magnetic resonance spectroscopy (MRS) of metabolites,
and mtDNA analysis.3,7,31,40–53 Additional indicators include observation
of mitochondrial proliferation, abnormalities on muscle histology (e.g.,
ragged red fibers or succinate dehydrogenase-positive fibers),41,54 and
abnormalities in electron microscopy.46,55 However, muscle histology
may be normal despite the presence of biochemical abnormalities in
the tissue. The determination of whether MD is present in a given
patient can be extremely complex, given that (i) mitochondrial
function can be secondarily affected due to the disease processes in
non-mitochondrial diseases, (ii) there can be extensive variability in
the distribution of abnormal mitochondria within an individual patient,
allowing a “false negative” testing profile to occur when tissues with
mitochondrial abnormalities are not tested, and (iii) there are no
uniform, definitive pathological abnormalities that distinguish all MD
patients from patients with other disorders. Diagnosis may ultimately
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rely on the application of diagnostic algorithms to predict the likelihood
of MD56,57 but MD is currently an under-diagnosed disease.4,58–64
Mechanistic information on MD has largely arisen from
mitochondrial electron transport chain component activity assays on
the components, isolated from their native matrix from fresh or frozen
tissue, or from cultured cells. These assays are, like most clinical
biochemical assays, performed under non-physiologic basal conditions
and with very different substrate concentrations than are seen in-vivo.
Complex interactions between the substrates of these assays and
other cellular components can lead to erroneous results65 though these
problems can, in principle be, overcome with careful isolation of
proteins or in-gel assays. Assays of activities outside of the intact
mitochondrial environment cannot identify defects in mitochondrial
membrane potential or coupling. In clinical practice, it has been found
that the methodological variations, limitations and difficulties
associated with the use of respiratory chain functional assays as a
diagnostic method for MD has led to massive inter-laboratory
variability in results.66 In alternative approaches, substrates are added
to whole cells or isolated mitochondrial preparations, and either
oxygen consumption or ATP generation is measured [reviewed in]67
While recognized as the current standard for mitochondrial testing
there are, again, significant limitations. Most apparent is the
requirement for viable functioning mitochondria, requiring cell
preparation or mitochondrial isolation and testing to be carried out
temporally, and therefore geographically, proximate to the biopsy. The
process of isolating mitochondria from native tissue risks damage and
places the organelle outside of a truly physiologic condition.
Conversely, whole cell assays require permeabilization of the cell to
the substrates and transport to the mitochondria. The potentially
limited ability to get reagents to the site of action can lead to a loss of
sensitivity and specificity. In all of the currently employed assays, the
mitochondrial function is not assessed in its native-organ context in
the human and the need persists for an assay that measures the
functional ability of mitochondria in an intact tissue preserved in a
state as close as possible to that in situ.
Electron paramagnetic (spin) resonance (EPR, ESR) is a
technique that can provide unique insight into mitochondrial status.
EPR detects and characterizes free radicals and many transition metal
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ions and clusters in biological systems by measuring the magnetic field
dependence of the absorption of microwave radiation at a given
frequency by the unpaired electrons residing in these species.68 The
mitochondrial respiratory chain Complexes I – IV are particularly rich
in transition metal-containing redox centers, with a complement of 21
centers that include heme iron, copper, and [2Fe2S], [3Fe4S] and
[4Fe4S] iron sulfur (FeS) clusters. Up to 18 of these adopt EPRdetectable paramagnetic states in native mitochondria and are readily
observed at temperatures close to liquid helium (10 – 40 K).69 The
spin-Hamiltonian parameters, midpoint potentials and relaxation
behavior of these centers have been reasonably well characterized,69–87
along with some other tissue-specific signals from transferrin,
ceruloplasmin, and catalase.88–90 Specific applications of EPR to
mitochondria have included detection of an irreversible deficiency in
Complex I FeS clusters in iron-deficient rats,91 heme-nitrosyl in
substantia nigra of Parkinson’s diseased brain,92 chromium-dependent
inhibition of Complexes I & II and aconitase,93 cardio- and neuroprotection against doxorubicin,80 prophylaxis against 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine in a Parkinson’s mouse model,82 the
differential sensitivity of aconitase and FeS clusters from Complexes I
& III to oxidative and nitrosative stress in heart,94 and the sensitivity
of Complex III FeS clusters in aging heart to ischemia.95 However,
despite these successes in mechanistic studies, the authors are
unaware of any direct application of EPR for functional
pathophysiologic studies in humans or whole animal models with
primary mitochondrial disease; the closest analog is a study in which a
comparison of EPR signals from muscle biopsies of sepsis patients
indicated significant depletion of Complex I FeS signals in those who
died compared to survivors.86,96
One group of MD that has been recently well-characterized and
suggests itself as a promising model for evaluation of new
pathophysiologic methodologies is the mitochondrial DNA (mtDNA)
depletion syndromes (MDS). MDS comprises a genetically and clinically
heterogeneous group of autosomal recessive diseases characterized by
a reduction in tissue-specific mtDNA copy number. This reduction is a
result of molecular defects in either the genes responsible for mtDNA
biogenesis, or those required for the maintenance of deoxynucleotide
pools or mtDNA integrity.97–99 The loss of mtDNA can lead to a variety
of clinical presentations that are dependent on the gene involved and
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the nature of the mutation. Depletion of mtDNA is the most common
cause of multi-systemic oxidative phosphorylation defects,100 with
deoxyguanosine kinase (DGUOK) deficiency being the most frequent
cause. Death commonly results from liver failure,26,97,101,102 which may
occur in the context of natural disease progression, exposure to
sodium valproate103–105 or complications of viral infections such as
influenza.55,106 Less severe attenuation of DGUOK function may result
in a susceptibility to isolated liver failure97,107,108 or a myopathic
presentation of DGUOK deficiency.109 Some cases with milder
mutations have required liver transplantation, with its attendant
complications, and may subsequently develop myopathy.97,108 Over the
preceding 5 years, we have developed an accurate method for assay
of tissue-specific mitochondrial DNA content using quantitative realtime polymerase chain reaction (qPCR) that has led to accurate
retrospective modeling and prospective diagnosis of patients with
hepatic mtDNA depletion.55,110–116 This is accepted as the clinical
standard for diagnosis of mtDNA depletion.54 The development of a
robust diagnosis for MDS and the detailed characterization of DGUOK
deficiency, in particular, suggested to us that an animal model of
DGUOK deficiency would be of great value in developing and
evaluating the potential of new diagnostic and pathophysiologic
techniques for MD.
In the present work, we aim to introduce EPR of tissue samples
at cryogenic temperatures as a mechanistic tool for MD. We have
developed a rat model of DGUOK deficiency (referred to by the trivial
name “DGUOK”) that exhibits characteristic biomarkers, and we have
applied standard biochemical and pathological tests along with EPR.
The goals of this work are to characterize the DGUOK rat in terms of
mitochondrial dysfunction and pathological outcome, and to evaluate
EPR as a new and additional technique in an integrated
characterization of MD.

Materials and Methods
The DGUOK rat model of DGUOK deficiency
Previously described zinc-finger nuclease (ZFN) technology was
employed.117,118 A preferred binding/cutting site of
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GTCGGTTCCTTCTGCgtagacTCCGAGCGTCTTTCCG was identified from a
clinically relevant transcript of DGUOK and the appropriate ZFN was
obtained from Sigma Aldrich (CompoZr Custom ZFN Service). This was
injected into the pronucleus of a fertilized one-cell embryo. These
microinjected embryos were then implanted into a “pseudo-pregnant”
recipient female rat. This resulted in the generation of four
characterized DGUOK rat knockout lines named SSdguokM1 SSdguokM2
SSdguokM3 and SSdguokM4. Because of the rare potential for an off-target
effect, where ZFNs cause double-strand breaks and mutations at
undesired loci, we backcrossed and bred homozygote animals from
these two lines.117 The “M1” line has a 31 base pair deletion after
amino acid six leading to a premature stop codon, i.e., a polypeptide
with 34 amino acids (the first 6 from the original protein sequence and
28 from the missense). Similarly, the “M2” line has a 37 base pair
amino acid deletion after amino acid six. This frame-shift mutation
would lead to a 42 amino acid polypeptide with only the first 6 amino
acids consistent with the original protein sequence.
The M3 line had a net 57bp frameshift deletion in exon 1
including the initiation codon which is predicted to lead to the use of
an alternate start codon in exon 1 with a 5′ truncated protein devoid of
the mitochondrial targeting sequence. The M4 line had an in-frame
deletion of 9 nucleotides in the targeting sequence. This strain does
not have hepatic mtDNA depletion and, because of the adequacy of
the first two models, was not further characterized.
The generation of the animal model and all subsequent animal
experiments were performed under approved Animal Use Application
by the Institutional Animal Care and Use Committee (IACUC) of the
Medical College of Wisonsin (protocols 2214 and 1764, respectively).

mtDNA assay
Real time analysis was performed as previously published and
validated in humans55,97,112 using rat specific primers. DNA was
extracted using Qiagen Blood Core Kit #158389 and quantified using
the Quant-iT PicoGreen double stranded DNA kit (Invitrogen) and a
Varioskan plate reader (Thermo Fisher) in 96 well format. DNA is
diluted to a concentration falling with in efficiency range of the assay
0.125–4 ng/l. qPCR was carried out on 10 μl samples, each containing
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between 0.35 and 12 ng of extracted DNA, 5 pmol of each forward and
reverse primer, and 5 μl iTAQ SYBR Green Supermix with ROX
(BioRad). The mitochondrial genome-targeted rat-specific primers
used were tRNALeu F: GGTTATTAGGGTGGCAGAGC and tRNALeu
R:GGAAGGCCATGGCAATTAAG. Nuclear primers, targeted to the ActB
coding region, were ActB F:TACCACTGGCATTGTGATGG and ActB R:
ACGCTCGGTCAGGATCTTC. The Basic Local Alignment Search Tool
(National Center for Biotechnology Information) was used to show that
primers hybridized to unique sequences in Rattus norvegicus. The realtime qPCR cycling conditions were (i) 50°C for 2 min, (ii) 95°C for 10
min, (iii) 45 cycles of 15 seconds at 95°C, and (iv) a combined 62°C
anneal/extension for 30 seconds. Upon completion of 45 cycles, a preprogrammed dissociation step was carried out by one cycle of 95°C for
15 seconds, 50°C for 15 seconds and 95°C for 15 seconds. Real-time
fluorescence was measured and analyzed on a 7900HT Fast Real-Time
PCR system (Applied Biosystems, Foster City, CA) using SDS V2.3
software. All samples were assayed in triplicate. The relative mtDNA
copy number was determined from the threshold difference between
the averages of each set of triplicate reactions.

Histology
A portion of each heart, lung, liver, spleen, and kidney from 4
wild-type SS rats and 5 SSdguokM2DGUOK rats at 11 months of age was
fixed in formalin for histological analysis. Fixed tissue was paraffinembedded, sectioned, and stained with hematoxylin and eosin (H&E)
using standard techniques. To evaluate possible liver fibrosis, sections
of liver were also stained using Masson trichrome stain using standard
techniques. For evaluation of muscle pathology, a quadriceps muscle
from each animal was frozen in isopentane at −78.5 °C, and 8 μm
cryosections were stained for H&E, Gomori trichrome, reduced
nicotinamide adenine dinucleotide (NADH), cytochrome oxidase (COX),
and succinate dehydrogenase (SDH) using standard techniques.

Protein immunoblot (western blot)
Protein homogenates prepared from the quadriceps muscle were
evaluated for mitochondrial electron transport chain complex
expression using standard western blot techniques.119 Transferred
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proteins were probed with a MitoProfile Total OXPHOS Blue Native WB
Antibody Cocktail (MitoSciences #MS603, Abcam, Cambridge, MA),
which includes antibodies against mitochondrial respiratory chain
complexes I–V, and visualized using enhanced chemiluminescence.
Quantification was performed using ImageJ version 1.44p and
statistics were evaluated using Student’s t-test.

Electron transport chain activity assay
Electron transport chain activity assays were carried out on
frozen rat muscle and liver (n = 6 for controls and n = 5 for DGUOK
rats) according to protocols previously described in detail120,121 with the
modification that the linear initial velocity in the first minute was
determined for Complex III, instead of a formal rate constant, due to
the lower activity compared to Complexes I, II and IV. The activities of
Complexes I – IV were normalized for mitochondrial content by
dividing by citrate synthase activity. The results of electron transport
chain activity assays are not normally distributed but become so after
transformation to their natural logarithms. Results are expressed as
average values and the standard error of the mean. Significance is
expressed by the non-parametric Mann-Whitney U test on the raw
data and by Student’s t-test of the logarithmically transformed data.
Blue native PAGE analysis with in-gel activity staining was carried out
as previously described.121–123 This allowed the identification of
decreased synthesis of mitochondrial subunits.124

EPR spectroscopy
Fresh tissue samples for EPR were rapidly extruded into 3 mm
diameter EPR tubes and frozen in liquid nitrogen within 90 s of harvest
(we have found that tissue can be frozen much more rapidly than
dilute aqueous solutions and with much reduced risk of the EPR tube
breaking). Samples entirely filled the active length of the EPR
resonator. EPR spectra were recorded on a Bruker EleXsys E600
spectrometer equipped with a Super-X microwave bridge with
integrated microwave counter, an ER4112SHQ resonant cavity
operating at 9.38 GHz, and an Oxford Instruments ESR900 helium flow
cryostat and ITC503 temperature controller. Spectra were recorded
with 10 G magnetic field modulation at 100 kHz and this modulation
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amplitude determined the spectral resolution. Microwave powers and
temperatures are given in the figure legends. Scans of 4096 points,
8000 G field envelope and 3 min duration were averaged over 60 –
180 min to provide the final spectrum. A background spectrum
collected on frozen water was subtracted from rat tissue spectra.
Experimental spectra were modeled by fitting a library of computed
spectra corresponding to the mitochondrial respiratory chain centers
and the [3Fe4S] cluster of aconitase,69 using a Levenberg-Marquardt
algorithm to minimize χ2 (IGOR Pro v. 6.32A, Wavemetrics, Lake
Oswego, OR). The contributions of each component were constrained
to ≥ 0. Correlation matrices indicated strong interdependencies
(correlation coefficients ~ 0.7) of contributions from the pairs of
signals (i) Complex II S3 3Fe4S and aconitase 3Fe4S, and (ii) Complex
I N1b and N2 FeS clusters. N1b and N2 could not be deconvoluted and
only the overall contribution from N1b + N2 is given, whereas S3 and
aconitase were deconvoluted by the use of two temperatures.69
Computed spectra of the individual components were calculated with
XSophe (Bruker Biospin;125,126) using spin Hamiltonian parameters
from the literature,69–79 and computed spectra were normalized for the
intensity of ∫χ″.dH (i.e. the first integral of the EPR absorption, or socalled “double-integrated spectrum”) prior to fitting to the
experimental data.

Results
Recapitulation of mtDNA depletion in DGUOK rat
To evaluate the phenotype, three M2, four M1 and six SS 8week-old females were sacrificed and tissue harvested. DNA was
extracted and subject to qPCR evaluation using validated rat-specific
primers, but otherwise as previously described.112 This method
demonstrates an approximately 90% reduction in hepatic mtDNA
content (Figure 1). This reduction is similar to the 80–90% reduction
in hepatic mtDNA seen in humans with this disorder.112 Similarly, a
60–80% reduction in splenic DNA content was observed.100 The
situation was less clear in muscle; while M1 rats exhibited about 60 %
depletion in mtDNA, the mtDNA level in the M2 rat was
indistinguishable from that in wild-type. Consequently mtDNA content
was assessed in sections of the same tissue that was used for
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Histology, ETC and EPR assays. This demonstrates no significant
difference in mtDNA content in skeletal muscle, regardless of
predominant oxidative fiber type (Table S1).

Figure 1: Absolute mtDNA content in DGUOK rats
The mtDNA copy numbers for eight week old M1 and M2 DGUOK knockout rats
compared with wild-type (SS) rats. The error bars indicate standard deviations for n =
6 (SS), n = 4 (M1) and n = 3 (M2).

Pathology of the DGUOK rat
A pathological analysis was performed on 4 wild-type and 5
DGUOK rats at approximately 11 months of age, including the
histological evaluation of heart, lung, liver, spleen, kidney, and
muscle. H&E-stained sections of heart, lung, liver, spleen, and kidney
revealed no apparent differences in the organ histology when
comparing wild-type and DGUOK rats. Liver fibrosis was further
evaluated using Masson trichrome staining, which also showed no
evident differences between wild-type and DGUOK livers. In contrast,
there were marked differences on oxidative enzyme staining when
comparing the quadriceps muscles of wild-type and DGUOK rats
(Figure 2). While pathological differences were not apparent on H&E
staining, there were numerous fibers that showed negative staining on
both cytochrome oxidase (COX) and succinate dehydrogenase (SDH)
stains (Figure 2). Large numbers (up to 20–30% of fibers) of these
COX negative/SDH negative fibers were seen in all DGUOK rats,
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whereas they were essentially absent in all of the wild-type rat
muscles examined.

Figure 2. Skeletal muscle pathology in 11 month old WT and DGUOK rats
Quadriceps muscles from DGUOK rats display little differences on H&E staining in
comparison to WT littermates. In contrast, staining for COX and SDH reveals
numerous fibers in DGUOK rat muscle that are negative for both COX and SDH,
whereas no such fibers were evident in WT rat muscle. The bar at the bottom, right
corresponds to 200 μm.

Expression of respiratory chain complexes
Mitochondrial protein expression was found to be altered in
quadriceps muscle of the 11 month old DGUOK rat (Figure 3).
Specifically, the data indicated that Complex I was significantly underexpressed (54 % of wild-type; p = 0.05) and suggested that Complex
III was also under expressed (47 % of wild-type; p = 0.12). The
expression levels of Complexes II, IV & V were unchanged in DGUOK
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rat muscle. Varying, though generally low, amounts of an unidentified
immunoreactive protein with Mr ≈ 30 kDa were also observed.

Figure 3. Respiratory chain complex expression in DGUOK rat muscle
Western blots of mitochondrial electron transport chain complexes I–V and GAPDH
from stripped membranes of quadriceps muscle from 11 month old wild-type and
DGUOK rats are shown in the top panel. The results of quantitation of the respiratory
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chain complex bands are shown below, normalized for GAPDH expression. The error
bars indicate standard errors for n = 4.

Electron chain transport assays
Significantly lower activities for Complexes I, III and IV were
observed in DGUOK rat liver, corresponding to about 20 %, 7 % and
13 % of wild-type activity, respectively, whereas Complex II activities
were statistically indistinguishable (Figure 4, Table 1). In DGUOK
muscle, the activities of Complexes I and III were only 9 % and 20 %
of wild-type, respectively, whereas Complex II and IV activities were
essentially indistinguishable.

Figure 4. Electron transport chain functional assays of Complexes I– IV
The functional activities of Complexes I – IV from liver and quadriceps muscle of
DGUOK rat are shown, normalized for mitochondrial content (as citrate synthase
activity) and expressed as percentages of activities from wild-type. Detailed results
are given in Table 1 (or S1).
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Table 1. Results of electron transport chain assays of Complexes I – IV from
muscle and liver from wild-type and DGUOK rats
TISSUE
Activity
assayed

1000 × Wild-type 1000 × DGUOK
Mannt-Test with
activity ÷ citrate activity citrate ÷ Whitney U
transformed data
synthase activity synthase activity test p-value p-value

LIVER
Complex I 230.08 ± 18.81

47.64 ± 9.53

0.008

0.002

Complex
II

991.9 ± 95.3

1291.6 ± 258.3

0.522

0.250

Complex
III

14.35 ± 0.80

1.02 ± 0.20

0.008

0.001

Complex
II – III

430.1 ± 32.6

129.3 ± 25.9

0.029

0.012

Complex
IV

137.54 ± 11.69

17.70 ± 3.54

0.014

0.002

Complex I 108.1 ± 8.25

9.73 ± 4.25

0.008

0.015

Complex
II

278.1 ± 16.42

215.8 ± 18.41

0.522

0.093

Complex
III

3.43 ± 0.48

0.70 ± 0.18

0.036

0.025

Complex
II –III

263.7 ± 28.53

157.6 ± 15.36

1.00

0.070

Complex
IV

38.63 ± 5.60

53.93 ± 8.76

0.412

0.434

MUSCLE

EPR spectroscopy
The EPR spectra at 12 K of liver, quadriceps muscle and heart
from wild-type and DGUOK rats are shown in Figure 5. The signals are
complex but some features are immediately identifiable and are
labeled a – k in Figure 5. Feature a at g′ ~ 6 is due to high-spin
ferriheme; b at g′ ~ 4 is due largely to Fe(III) in transferrin; a
complex pattern extending upfield from c is due to Mn(II), which is
prominent in liver but much less so in quadriceps muscle and not
detectable in heart, and overlaps the signals from the respiratory chain
iron sulfur clusters; the prominent feature at d is the so-called “g =
2.01” signal and is due to overlapping signals from the oxidized 3Fe4S
clusters of Complex II and oxidatively-damaged aconitase; the signal
at e, the so-called “g = 1.94” signal, is due to overlapping g2
resonances from reduced 2Fe2S and 4Fe4S clusters, primarily those
from Complex I; the signals at f are the g3 resonances from Complex I
N4 4Fe4S (lower field) and Complex I N3 2Fe2S (higher field) and are
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overlaid on the highest field mI = 5/2 resonance of the mS = ½
manifold of S = 5/2 Mn(II) (the latter is not clear in trace A but much
more pronounced in trace B); the resonances labeled g are gx and gy
of the rhombic high-spin ferriheme of catalase;88 the resonances
around h are due to low-spin ferriheme; feature i is the g1 (gx)
resonance of low-spin heme a of Complex IV; and k indicates the g1
(gx; lower field) and g3 (gz; higher field) resonances from the Rieske
2Fe2S cluster of Complex II. The broad EPR absorption in the liver
spectra from about 2000 G is largely due to rapid-passage of the
Mn(II) leading to an absorption-like signal that includes components
from the mS = 3/2 and mS = 5/2 manifolds,127 along with some
contribution from CuA of Complex IV.

Figure 5. 12 K EPR spectra from wild-type and DGUOK rat tissue
The spectra are from samples of A, wild-type rat liver; B, DGUOK rat liver; C, wildtype rat quadriceps muscle; D, DGUOK rat quadriceps muscle; E, wild-type rat heart;
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and F, DGUOK rat heart. In each case, the sample completely filled the part of the EPR
tube that occupied the active region of the resonator. A & B shown × 1, C & D are
shown × 2, and E & F shown × 0.5. Spectra were recorded at 12 K, 2.5 mW power.
The lower-case labels identify specific signals in the spectra: (a) high-spin axial
ferriheme g⊥; (b) transferrin non-heme Fe(III); (c) the mI = 5/2 line at the low-field
extremity of the six-line Mn(II) hyperfine pattern; (d) overlapping signals from
aconitase and S3 [3Fe4S] clusters; (e) overlapping g2 resonances from Complex I
[2Fe2S] and [4Fe4S] clusters; (f) resolved g3 resonances from N4 and N3 clusters; (g)
high-spin catalase gx and gy lines; (h) low-spin catalase resonances; (i) heme a g1;
and (k) Rieske [2Fe2S] cluster g1 and g3 resonances.

Visual inspection of the spectra provides some limited
information. Mn(II) is clearly elevated in DGUOK liver whereas the
reduced Complex I FeS signals (e, f) are diminished. In DGUOK
quadriceps muscle, the Complex I FeS signals and the Complex III
Rieske signals are markedly diminished compared to wild-type. In both
muscle and liver, the g = 2.01 signal (d) due to Complex II S3 and/or
aconitase appears elevated in DGUOK compared to wild-type. To
further investigate this phenomenon, spectra were recorded at 40 K
(Figure 6) where the faster-relaxing S3 signal intensity is lowered
relative to the more slowly relaxing aconitase signal. In liver, the
difference in intensity of the g = 2.01 signal persists and we assign
this as being due to a 25 % increase in the aconitase signal in DGUOK
over wild-type. In quadriceps muscle at 40 K, the DGUOK signal is now
smaller than the wild-type signal, indicating that the difference at 12 K
is due to elevated amounts of oxidized Complex III S3 3Fe4S. Clear
signals due to g1 (gx) of heme a of Complex IV were only observed in
heart. The signals in liver and quadriceps were much broader and
suggestive of a distribution of g-values; this resonance position of this
signal was found to be very sensitive to mutations in bacterial
cytochrome c oxidase128 and the apparent distribution of g1 values may
reflect multiple environments in liver mitochondria. In liver, the signal
from transferrin was elevated and that from catalase was depressed.
Interestingly, no significant differences at all were observed between
the EPR spectra of heart from wild-type and DGUOK rats.
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Figure 6. 40 K EPR spectra from wild-type and DGUOK rat tissue
The spectra are from samples of A, wild-type rat liver (solid line) and DGUOK rat liver
(dashed line); and B, wild-type rat quadriceps muscle (solid line) and DGUOK rat
muscle (dashed line). Spectra were recorded at 40 K, 2.5 mW power.

For quantitative information we turned to computer simulation
of the spectra. Figure 7 shows the g ~ 2 region of the experimental
spectra for liver (A, B), quadriceps muscle (E, F) and heart (I, J) from
DGUOK and wild-type rats. In each case, fits to the library of
computed spectra were generated. As we are particularly interested in
the differences between wild-type and DGUOK, difference spectra
(DGUOK minus wild-type) of the experimental data (C, G and K for
liver, muscle and heart, respectively) and the computed fits (D and H
for liver and muscle; no significant difference was observed between
the fits to wild-type and DGUOK heart) are presented. The
experimental and computed difference spectra match very well and
details of the fits are given in Table 2/Table S2. From the fit
parameters, and using the dual temperature study to resolve the S3
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and aconitase 3Fe4S contributions, we calculated the fractional
difference between the intensities of each of the components in the
DGUOK and wild-type tissues, and the significant results are
summarized in Figure 8.

Figure 7. Quantitative analysis of the 12 K EPR signals from wild-type and DGUOK rat
tissues
Traces A, B, E, F, I and J show the g′ ~ 2 region of the EPR spectra of A, wild-type rat
liver; B, DGUOK rat liver; E, wild-type rat quadriceps muscle; F, DGUOK rat
quadriceps muscle; I, wild-type rat heart; and J, DGUOK rat heart. Trace C is the
difference spectrum obtained by subtraction of A from B, and is shown multiplied by a
factor of two; likewise, G = 2×(F − E) and K = 2×(J − I). Trace D is a theoretical
simulation of C generated by the subtraction of fits of A and B to model spectra of the
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paramagnetic species likely to be observed in the mitochondrion. Fitting parameters
are presented in Table 2 (or S2). Similarly, trace H is a simulation of J from fits to E
and F. No attempt was made to simulate K, as no significant differences were
observed between fits to I and J.

Figure 8. Summary of EPR of DGUOK rat liver and muscle
A comparison of signal intensities is shown for some of the respiratory complex redox
centers in liver and muscle from the DGUOK and wild-type rat. The standard errors
were calculated from those of the fit parameters, presented in Table 2 (or S2).

Table 2. Fitting parameters for the EPR signals from spectra of liver and
muscle tissue from wild-type and DGUOK rats. The absolute intensities of
each species (or group of species) are shown for wild-type and DGUOK, along
with the percentage differences between DGUOK and wild-type intensities in
brackets
EPR Signal

Liver
W/T

Liver DGUOK [Δ
(%)]a

Muscle
W/T

Muscle DGUOK [Δ
(%)]

Heartb

CuA

47 ± 13

44 ± 15 [NS]c

9±1

13 ± 1 [+45]

NDd
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EPR Signal

Liver
W/T

Liver DGUOK [Δ
(%)]a

Heme a

200 ± 50 100 ± 60 [−50]

Muscle
W/T

Muscle DGUOK [Δ
(%)]

Heartb

ND

ND

200 ± 30

High-spin heme 116 ± 7

71 ± 9 [−39]

44 ± 1

31 ± 1 [−30]

183 ± 3

N1b + N2

26 ± 5

16 ± 5 [−39]

28.2 ± 0.2

7.4 ± 0.5 [−74]

111 ± 1

FeS N3

17 ± 8

8 ± 5 [−53]

16 ± 1

5.5 ± 0.7 [−61]

38 ± 4

FeS N4

41 ± 8

20 ± 6 [−51]

33 ± 1

14 ± 1 [−59]

108 ± 4

All Complex I
FeS

84 ± 12

44 ± 9 [−49]

77 ± 1

26 ± 1 [−66]

257 ± 6

S3 + Acn

10.8 ±
1.6

15 ± 2 [+37]

1.3 ± 0.1

3.8 ± 0.1 [+192]

17 ± 1

FeS S1

27 ± 10

29 ± 13 [NS]

15 ± 1

8±1

16 ± 5

FeS S2

ND

ND

ND

ND

60 ± 5

S1 + S2

27 ± 10

29 ± 13 [NS]

15 ± 1

8 ± 1 [−48]

76 ± 7

Rieske FeS

99 ± 11

98 ± 12 [NS]

37 ± 1

18 ± 1 [−51]

238 ± 5

Mn(II)

295 ± 27 588 ± 32 [+99]

32 ± 3

20 ± 2 [−35]

ND

aCalculated

as {[(DGUOK signal) − (wild-type signal)] ÷ (wild-type signal)}×100.
bWild-type and DGUOK heart were indistinguishable.
cNot significant.
dNone detected.

Discussion
The aims of this work are to describe the DGUOK rat
mitochondrial phenotype and evaluate it as a model for mitochondrial
disease, and to apply EPR spectroscopy of tissue to enable an
understanding of what happens at the electron level in tissue with
mtDNA depletion. The DGUOK rat has a complex and tissue-dependent
mitochondrial phenotype. The DGUOK liver exhibited markedly lower
mtDNA copy number, ~ 10 % of wild-type. However, EPR showed that
Complex I FeS clusters were present at least 50 % as much as in wildtype, and signals from S1, S2, S3 and the Rieske FeS clusters
indicated that Complexes II and III are expressed at the same level as
in wild-type. The observation that the four EPR-detectable FeS cluster
signals are depleted by the same amounts, despite very different
redox potentials, and that signal intensities from both the S1–S2 pair
and the Rieske cluster are indistinguishable from wild-type suggests
that (i) the lowered Complex I signals are due to depressed expression
or Fe incorporation, rather than an elevated redox potential, and (ii)
the depleted Complex I complement therefore provides sufficient
electrons to load the electron transfer chain. The aconitase 3Fe4S
signal, a characteristic marker for oxidative stress,82 was elevated in
DGUOK liver. Also, Mn(II), which is present at high levels in wild-type
liver and is proposed to be additionally generated in response to
Free Radical Biology and Medicine, Vol 92 (March 2016): pg. 141-151. DOI. This article is © Elsevier and permission has
been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article
to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

22

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

oxidative stress,127 was doubled compared to wild-type. The activities
of Complexes I, III and IV in DGUOK liver were very depressed
compared to wild-type, and by far more that can be accounted for by
expression levels. It is tempting to speculate that the oxidative stress
identified by the aconitase and Mn(II) EPR signals is either a cause or
consequence of the additional Complex I, II and IV dysfunction in
DGUOK liver. The very low levels of Complexes III and IV activities
explain the EPR observation that the electron transfer chain remains
electron-rich, and the redox potential maintained close to the
NADH:NAD midpoint potential, even though Complex I activity is also
significantly depressed. The elevation of the EPR signal from
transferrin may indicate some hemorrhaging, and the depression of
the catalase signal also suggests some disease or damage to the
liver.129
The mitochondrial phenotype in DGUOK quadriceps muscle is
also complex. Consistent with muscle evaluated in humans with severe
disease, protein expression levels for Complexes I and III were also ~
50 % of wild-type, whereas Complexes II, IV and V were expressed at
wild-type.108 However, in contrast to humans with severe disease, the
mtDNA copy numbers for wild-type and M2 DGUOK were similar across
all muscle groups [table S1]. This lack of difference in the muscle
types may reflect variability in sampling, the milder phenotype in the
rats or an underlying correction in muscle tissue for example by de
novo purine synthesis or alternate salvage pathways. This data
underscores the limited sensitivity of qPCR previously described in
human muscle112 and emphasizes the need to consider evaluation of
liver specifically for depletion in this disease.
Consistent with protein expression levels, EPR of DGUOK
quadriceps muscle indicated that Complex I is present at ≥ 35 % of
the wild-type level and Complex III at about 50 %. The EPR data for
Complex II are revealing. The S3 cluster signal was twice as intense as
in wild-type, yet the S1 and S2 clusters were diminished by a factor of
two. This could indicate a catastrophic inability to correctly assemble
Complex II or incorporate S1 and S2 but this would be expected to
essentially abolish activity, and the elevation of S3 would require a
doubling of Complex II expression. Neither phenomenon was
observed. More likely, the changes in S1, S2 and S3 reflect a Complex
II that experiences a significantly more oxidizing redox potential than
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in wild-type mitochondria. This hypothesis is strongly supported by the
very low Complex I electron transferring activity compared to the
downstream activities of Complexes II, III and IV. Therefore, Complex
II is drained of electrons and produces the EPR signature observed in
DGUOK quadriceps muscle. This scenario also explains the lack of
markers for oxidative stress in the EPR signature of DGUOK muscle. In
the absence of Complex I activity, very few electrons enter the
respiratory chain to begin with. Furthermore, the downstream
components are in a more oxidized state and thus are primed to
receive any electrons that do enter the respiratory chain, essentially
acting as antioxidants. So, while Complex III dysfunction results in
electron buildup and oxidative stress in DGUOK liver, the lack of
activity of Complex I and downstream oxidation of Complexes II – IV
in muscle does not result in oxidative stress even though Complex III
activity is as depressed in muscle as it is in liver. The only EPR marker
observed for Complex IV in this study, the heme a signal, was very
weak and broad in muscle and was not significant in the fits.
Nevertheless, visual examination suggests a comparable signal in wildtype and DGUOK, consistent with the significant Complex IV activity.
What remains unclear is the reason(s) behind the low activities of
Complexes I and III. Native PAGE provides no evidence for subunit
depletion, and EPR does not indicate oxidative stress.
In contrast to liver and quadriceps muscle, the heart in the
DGUOK rat appears entirely unaffected. The mtDNA copy numbers are
normal and the EPR signals of wild-type and DGUOK heart are
indistinguishable themselves and very similar to wild-type quadriceps
muscle. Large EPR signals from Complex I N3 and N4, a large signal
from Complex III Rieske 2Fe2S, a high ratio of the g = 1.94 and g =
2.01 signals, and a weak signal from Complex IV heme a all indicate a
very reducing environment that is consistent with an active Complex I
and a fully functioning respiratory chain that does not produce
oxidative stress.
EPR is a unique tool in that it can interrogate the status of the
mitochondrion at the time of freezing, in unprocessed viable biological
samples. First, it is clear that in both liver and quadriceps muscle, EPR
identified mitochondrial dysfunction in the DGUOK rat. Second, some
mechanistic information on the DGUOK rat was obtained. In liver, the
EPR results indicated that the reduced electron transfer chain activity
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of Complexes I is in part due to reduced expression but that the very
low activity of Complex, III is not a consequence of reduced
expression or Fe incorporation as FeS clusters. The retention of the
Complex III Rieske 2Fe2S EPR signal in DGUOK liver indicates that
Complex III is present at wild-type levels, incorporates the Rieske
cluster, and electrons can progress through the respiratory chain at
least as far as the Rieske cluster. The reason for Complex III inactivity
remains unknown but appears to be downstream of the Rieske cluster.
Oxidative stress may be important, and two independent markers for
oxidative stress were identified, elevated aconitase 3Fe4S and Mn(II);
two markers for liver damage were also identified, depressed catalase
and elevated transferrin. In quadriceps muscle, EPR provides
complementary information to the activity assays. The lack of Complex
I activity and the EPR identification of oxidation of the three Complex
II FeS clusters provides a rationale for the lack of any EPR markers for
oxidative stress in muscle. A knowledge of whether oxidative stress is
a consequence of mitochondrial disease, and in which tissues and why,
is an important piece of information that may inform therapy choices.

Conclusions
The DGUOK rat capitulates major biochemical features observed
in humans with DGUOK deficiency, specifically significantly reduced
mtDNA content, reduced mitochondrial complex I, III and IV protein
content and enzymatic activity in frozen liver. EPR assessment of
flash-frozen tissues has demonstrated dramatic differences in the
mitochondrial electron transport chain status in situ compared with
wild-type animals. The reproducibility and magnitude of these
differences is encouraging given the relatively mild pathologic
differences seen in the animals. It suggests that EPR may be able to
reliably distinguish individuals with mitochondrial disease from distinct
etiologies of muscle or liver disease in humans.
Highlights
•
•
•

A rat model of DGUOK deficiency approximates the human disease
EPR is sensitive for detecting mitochondrial functional abnormality
in situ.
EPR shows how the respiratory chain is affected by mitochondrial
disease.
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•
•

EPR has a role in mechanistic pathophysiological studies of
mitochondrial disease
There is strong potential for EPR as an additional diagnostic tool.

Abbreviations
COX

cytochrome oxidase

M2

deoxyguanosine kinase-deficient rat model

DGUOK

deoxyguanosine kinase

EPR
(ESR)

electron paramagnetic (spin) resonance

FeS

iron-sulfur (cluster)

H&E

hematoxylin and eosin

MD

mitochondrial disease

MDS

mitochondrial DNA depletion syndrome

MPV17

mitochondrial inner membrane protein

mtDNA

mitochondrial DNA

NADH

reduced nicotinamide adenine dinucleotide

POLG

DNA polymerase γ

SDH

succinate dehydrogenase

TWINKLE

a mitochondrial DNA helicase encoded by chromosome 10, open
reading frame 2 (also known as C10orf2)
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Abstract.
A novel rat model for a well-characterized human mitochondrial disease, mitochondrial DNA depletion
syndrome with associated deoxyguanosine kinase (DGUOK) deficiency, is described. The rat model
recapitulates the pathologic and biochemical signatures of the human disease. The application of electron
paramagnetic (spin) resonance (EPR) spectroscopy to the identification and characterization of respiratory
chain abnormalities in the mitochondria from freshly frozen tissue of the mitochondrial disease model rat is
introduced. EPR is shown to be a sensitive technique for detecting mitochondrial functional abnormality in situ
and, here, is particularly useful in characterizing the redox state changes and oxidative stress that can result
from depressed expression and/or diminished specific activity of the distinct respiratory chain complexes. As
EPR requires no sample preparation or non-physiological reagents, it provides information on the status of the
mitochondrion as it was in the functioning state. On its own, this information is of use in identifying respiratory
chain dysfunction; in conjunction with other techniques, the information from EPR shows how the respiratory
chain is affected at the molecular level by the dysfunction. It is proposed that EPR has a role in mechanistic
pathophysiological studies of mitochondrial disease and strong potential as an additional diagnostic tool.

Keywords.
DGUOK, redox, oxidative, stress, mtDNA depletion, pathology

Graphical abstract.
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Highlights.
EPR demonstrates marked signal changes in a rat with DGUOK deficiency that resembles human disease

Abbreviations.
COX, cytochrome oxidase; M2, deoxyguanosine kinase-deficient rat model; DGUOK, deoxyguanosine kinase;
EPR (ESR), electron paramagnetic (spin) resonance; FeS, iron-sulfur (cluster); H&E, hematoxylin and eosin;
MD, mitochondrial disease; MDS, mitochondrial DNA depletion syndrome; MPV17 mitochondrial inner
membrane protein; mtDNA, mitochondrial DNA; NADH, reduced nicotinamide adenine dinucleotide; POLG,
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DNA polymerase γ; SDH, succinate dehydrogenase; TWINKLE, a mitochondrial DNA helicase encoded by
chromosome 10, open reading frame 2 (also known as C10orf2)
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Introduction.
Mitochondrial disease (MD) occurs where depletion of mitochondrial DNA (mtDNA) or mutations in
mtDNA and/or nuclear DNA (nDNA) lead to altered mitochondrial function.(1-4) Altered activities of Complexes
I – V have been identified and physiological consequences of mitochondrial respiratory chain defects include
reduced metabolic capacity, reduced ATP synthesis, and increased oxidative and nitrosative stress.(5-15)
Symptoms of MD are manifold and include weakness (from central nervous system, peripheral nerve, and/or
skeletal muscle disease), pain, intolerance of some general anesthetics and anti-epileptic drugs,
gastrointestinal disorders, ophthalmoplegia and/or visual failure, failure to thrive, cardiac and respiratory
disease, liver disease, diabetes, seizures, sensorineural hearing loss, mental retardation, dementia, movement
disorders, increased susceptibility to infection, and pregnancy loss.(1, 2, 16-38) Establishing diagnoses and
understanding the pathophysiology of mitochondrial disease (MD) has proven extremely challenging because
of the extraordinary range of clinical symptoms and testing abnormalities (39). MD is often suspected in early
childhood from clinical differential diagnosis of patients with diseases involving the brain, muscle, or liver.
Traditional methods for diagnosing MD include clinical presentation, family history, pathology, metabolic
profiling, enzyme activity levels, electrophysiology, magnetic resonance imaging (MRI) of brain and magnetic
resonance spectroscopy (MRS) of metabolites, and mtDNA analysis (3, 7, 31, 40-53). Additional indicators
include observation of mitochondrial proliferation, abnormalities on muscle histology (e.g., ragged red fibers or
succinate dehydrogenase-positive fibers) (41, 54), and abnormalities in electron microscopy (46, 55). However,
muscle histology may be normal despite the presence of biochemical abnormalities in the tissue. The
determination of whether MD is present in a given patient can be extremely complex, given that (i)
mitochondrial function can be secondarily affected due to the disease processes in non-mitochondrial diseases,
(ii) there can be extensive variability in the distribution of abnormal mitochondria within an individual patient,
allowing a “false negative” testing profile to occur when tissues with mitochondrial abnormalities are not tested,
and (iii) there are no uniform, definitive pathological abnormalities that distinguish all MD patients from patients
with other disorders. Diagnosis may ultimately rely on the application of diagnostic algorithms to predict the
likelihood of MD (56, 57) but MD is currently an under-diagnosed disease (4, 58-64).
Mechanistic information on MD has largely arisen from mitochondrial electron transport chain
component activity assays on the components, isolated from their native matrix from fresh or frozen tissue, or
5
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from cultured cells. These assays are, like most clinical biochemical assays, performed under non-physiologic
basal conditions and with very different substrate concentrations than are seen in-vivo. Complex interactions
between the substrates of these assays and other cellular components can lead to erroneous results (65)
though these problems can, in principle be, overcome with careful isolation of proteins or in-gel assays. Assays
of activities outside of the intact mitochondrial environment cannot identify defects in mitochondrial membrane
potential or coupling. In clinical practice, it has been found that the methodological variations, limitations and
difficulties associated with the use of respiratory chain functional assays as a diagnostic method for MD has
led to massive inter-laboratory variability in results (66). In alternative approaches, substrates are added to
whole cells or isolated mitochondrial preparations, and either oxygen consumption or ATP generation is
measured [reviewed in (67)]. While recognized as the current standard for mitochondrial testing there are,
again, significant limitations. Most apparent is the requirement for viable functioning mitochondria, requiring cell
preparation or mitochondrial isolation and testing to be carried out temporally, and therefore geographically,
proximate to the biopsy. The process of isolating mitochondria from native tissue risks damage and places the
organelle outside of a truly physiologic condition. Conversely, whole cell assays require permeabilization of the
cell to the substrates and transport to the mitochondria. The potentially limited ability to get reagents to the site
of action can lead to a loss of sensitivity and specificity. In all of the currently employed assays, the
mitochondrial function is not assessed in its native-organ context in the human and the need persists for an
assay that measures the functional ability of mitochondria in an intact tissue preserved in a state as close as
possible to that in situ.
Electron paramagnetic (spin) resonance (EPR, ESR) is a technique that can provide unique insight into
mitochondrial status. EPR detects and characterizes free radicals and many transition metal ions and clusters
in biological systems by measuring the magnetic field dependence of the absorption of microwave radiation at
a given frequency by the unpaired electrons residing in these species (68). The mitochondrial respiratory chain
Complexes I - IV are particularly rich in transition metal-containing redox centers, with a complement of 21
centers that include heme iron, copper, and [2Fe2S], [3Fe4S] and [4Fe4S] iron sulfur (FeS) clusters. Up to 18
of these adopt EPR-detectable paramagnetic states in native mitochondria and are readily observed at
temperatures close to liquid helium (10 - 40 K) (69). The spin-Hamiltonian parameters, midpoint potentials and
relaxation behavior of these centers have been reasonably well characterized (69-87), along with some other
6

Mitochondrial dysfunction and EPR abnormalities in DGUOK deficient rats

Bennett et al

tissue-specific signals from transferrin, ceruloplasmin, and catalase (88-90). Specific applications of EPR to
mitochondria have included detection of an irreversible deficiency in Complex I FeS clusters in iron-deficient
rats (91), heme-nitrosyl in substantia nigra of Parkinson's diseased brain (92), chromium-dependent inhibition
of Complexes I & II and aconitase (93), cardio- and neuro-protection against doxorubicin (80), prophylaxis
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a Parkinson's mouse model (82), the differential
sensitivity of aconitase and FeS clusters from Complexes I & III to oxidative and nitrosative stress in heart (94),
and the sensitivity of Complex III FeS clusters in aging heart to ischemia (95). However, despite these
successes in mechanistic studies, the authors are unaware of any direct application of EPR for functional
pathophysiologic studies in humans or whole animal models with primary mitochondrial disease; the closest
analog is a study in which a comparison of EPR signals from muscle biopsies of sepsis patients indicated
significant depletion of Complex I FeS signals in those who died compared to survivors (86, 96).
One group of MD that has been recently well-characterized and suggests itself as a promising model
for evaluation of new pathophysiologic methodologies is the mitochondrial DNA (mtDNA) depletion syndromes
(MDS). MDS comprises a genetically and clinically heterogeneous group of autosomal recessive diseases
characterized by a reduction in tissue-specific mtDNA copy number. This reduction is a result of molecular
defects in either the genes responsible for mtDNA biogenesis, or those required for the maintenance of
deoxynucleotide pools or mtDNA integrity (97-99). The loss of mtDNA can lead to a variety of clinical
presentations that are dependent on the gene involved and the nature of the mutation. Depletion of mtDNA is
the most common cause of multi-systemic oxidative phosphorylation defects (100), with deoxyguanosine
kinase (DGUOK) deficiency being the most frequent cause. Death commonly results from liver failure (26, 97,
101, 102), which may occur in the context of natural disease progression, exposure to sodium valproate (103105) or complications of viral infections such as influenza (55, 106). Less severe attenuation of DGUOK
function may result in a susceptibility to isolated liver failure (97, 107, 108) or a myopathic presentation of
DGUOK deficiency (109). Some cases with milder mutations have required liver transplantation, with its
attendant complications, and may subsequently develop myopathy (97, 108). Over the preceding 5 years, we
have developed an accurate method for assay of tissue-specific mitochondrial DNA content using quantitative
real-time polymerase chain reaction (qPCR) that has led to accurate retrospective modeling and prospective
diagnosis of patients with hepatic mtDNA depletion (55, 110-116). This is accepted as the clinical standard for
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diagnosis of mtDNA depletion (54). The development of a robust diagnosis for MDS and the detailed
characterization of DGUOK deficiency, in particular, suggested to us that an animal model of DGUOK
deficiency would be of great value in developing and evaluating the potential of new diagnostic and
pathophysiologic techniques for MD.
In the present work, we aim to introduce EPR of tissue samples at cryogenic temperatures as a
mechanistic tool for MD. We have developed a rat model of DGUOK deficiency (referred to by the trivial name
"DGUOK") that exhibits characteristic biomarkers, and we have applied standard biochemical and pathological
tests along with EPR. The goals of this work are to characterize the DGUOK rat in terms of mitochondrial
dysfunction and pathological outcome, and to evaluate EPR as a new and additional technique in an integrated
characterization of MD.

Materials and Methods.
The DGUOK rat model of DGUOK deficiency. Previously described zinc-finger nuclease (ZFN)
technology was employed (117, 118). A preferred binding/cutting site of
GTCGGTTCCTTCTGCgtagacTCCGAGCGTCTTTCCG was identified from a clinically relevant transcript of
DGUOK and the appropriate ZFN was obtained from Sigma Aldrich (CompoZr Custom ZFN Service). This was
injected into the pronucleus of a fertilized one-cell embryo. These microinjected embryos were then implanted
into a “pseudo-pregnant” recipient female rat. This resulted in the generation of four characterized DGUOK rat
knockout lines named SSdguokM1 SSdguokM2 SSdguokM3and SSdguokM4. Because of the rare potential for an off-target
effect, where ZFNs cause double-strand breaks and mutations at undesired loci, we backcrossed and bred
homozygote animals from these two lines (117). The “M1” line has a 31 base pair deletion after amino acid six
leading to a premature stop codon, i.e., a polypeptide with 34 amino acids (the first 6 from the original protein
sequence and 28 from the missense). Similarly, the “M2” line has a 37 base pair amino acid deletion after
amino acid six. This frame-shift mutation would lead to a 42 amino acid polypeptide with only the first 6 amino
acids consistent with the original protein sequence.
The M3 line had a net 57bp frameshift deletion in exon 1 including the initiation codon which is predicted
to lead to the use of an alternate start codon in exon 1 with a 5’ truncated protein devoid of the mitochondrial
targeting sequence. The M4 line had an in-frame deletion of 9 nucleotides in the targeting sequence. This
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strain does not have hepatic mtDNA depletion and, because of the adequacy of the first two models, was not
further characterized.
The generation of the animal model and all subsequent animal experiments were performed under
approved Animal Use Application by the Institutional Animal Care and Use Committee (IACUC) of the Medical
College of Wisonsin (protocols 2214 and 1764, respectively).
mtDNA assay. Real time analysis was performed as previously published and validated in humans (55,
97, 112) using rat specific primers. DNA was extracted using Qiagen Blood Core Kit #158389 and quantified
using the Quant-iT PicoGreen double stranded DNA kit (Invitrogen) and a Varioskan plate reader (Thermo
Fisher) in 96 well format. DNA is diluted to a concentration falling with in efficiency range of the assay 0.125-4
ng/l. qPCR was carried out on 10 l samples, each containing between 0.35 and 12 ng of extracted DNA, 5
pmol of each forward and reverse primer, and 5 l iTAQ SYBR Green Supermix with ROX (BioRad). The
mitochondrial genome-targeted rat-specific primers used were tRNALeu F: GGTTATTAGGGTGGCAGAGC
and tRNALeu R:GGAAGGCCATGGCAATTAAG. Nuclear primers, targeted to the ActB coding region, were
ActB F:TACCACTGGCATTGTGATGG and ActB R: ACGCTCGGTCAGGATCTTC. The Basic Local Alignment
Search Tool (National Center for Biotechnology Information) was used to show that primers hybridized to
unique sequences in Rattus norvegicus. The real-time qPCR cycling conditions were (i) 50°C for 2 min, (ii)
95°C for 10 min, (iii) 45 cycles of 15 seconds at 95°C, and (iv) a combined 62°C anneal/extension for 30
seconds. Upon completion of 45 cycles, a pre-programmed dissociation step was carried out by one cycle of
95°C for 15 seconds, 50°C for 15 seconds and 95°C for 15 seconds. Real-time fluorescence was measured
and analyzed on a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA) using SDS
V2.3 software. All samples were assayed in triplicate. The relative mtDNA copy number was determined from
the threshold difference between the averages of each set of triplicate reactions.
Histology. A portion of each heart, lung, liver, spleen, and kidney from 4 wild-type SS rats and 5
SSdguokM2DGUOK rats at 11 months of age was fixed in formalin for histological analysis. Fixed tissue was
paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) using standard techniques. To
evaluate possible liver fibrosis, sections of liver were also stained using Masson trichrome stain using standard
techniques. For evaluation of muscle pathology, a quadriceps muscle from each animal was frozen in
isopentane at -78.5 C, and 8 m cryosections were stained for H&E, Gomori trichrome, reduced nicotinamide
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adenine dinucleotide (NADH), cytochrome oxidase (COX), and succinate dehydrogenase (SDH) using
standard techniques.
Protein immunoblot (western blot). Protein homogenates prepared from the quadriceps muscle were
evaluated for mitochondrial electron transport chain complex expression using standard western blot
techniques (119). Transferred proteins were probed with a MitoProfile Total OXPHOS Blue Native WB
Antibody Cocktail (MitoSciences #MS603, Abcam, Cambridge, MA), which includes antibodies against
mitochondrial respiratory chain complexes I-V, and visualized using enhanced chemiluminescence.
Quantification was performed using ImageJ version 1.44p and statistics were evaluated using Student’s t-test.
Electron transport chain activity assay. Electron transport chain activity assays were carried out on
frozen rat muscle and liver (n = 6 for controls and n = 5 for DGUOK rats) according to protocols previously
described in detail (120, 121) with the modification that the linear initial velocity in the first minute was
determined for Complex III, instead of a formal rate constant, due to the lower activity compared to Complexes
I, II and IV. The activities of Complexes I - IV were normalized for mitochondrial content by dividing by citrate
synthase activity. The results of electron transport chain activity assays are not normally distributed but
become so after transformation to their natural logarithms. Results are expressed as average values and the
standard error of the mean. Significance is expressed by the non-parametric Mann-Whitney U test on the raw
data and by Student's t-test of the logarithmically transformed data. Blue native PAGE analysis with in-gel
activity staining was carried out as previously described (121-123). This allowed the identification of decreased
synthesis of mitochondrial subunits (124).
EPR spectroscopy. Fresh tissue samples for EPR were rapidly extruded into 3 mm diameter EPR tubes
and frozen in liquid nitrogen within 90 s of harvest (we have found that tissue can be frozen much more rapidly
than dilute aqueous solutions and with much reduced risk of the EPR tube breaking). Samples entirely filled
the active length of the EPR resonator. EPR spectra were recorded on a Bruker EleXsys E600 spectrometer
equipped with a Super-X microwave bridge with integrated microwave counter, an ER4112SHQ resonant
cavity operating at 9.38 GHz, and an Oxford Instruments ESR900 helium flow cryostat and ITC503
temperature controller. Spectra were recorded with 10 G magnetic field modulation at 100 kHz and this
modulation amplitude determined the spectral resolution. Microwave powers and temperatures are given in the
figure legends. Scans of 4096 points, 8000 G field envelope and 3 min duration were averaged over 60 - 180
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min to provide the final spectrum. A background spectrum collected on frozen water was subtracted from rat
tissue spectra. Experimental spectra were modeled by fitting a library of computed spectra corresponding to
the mitochondrial respiratory chain centers and the [3Fe4S] cluster of aconitase (69), using a LevenbergMarquardt algorithm to minimize 2 (IGOR Pro v. 6.32A, Wavemetrics, Lake Oswego, OR). The contributions
of each component were constrained to  0. Correlation matrices indicated strong interdependencies
(correlation coefficients ~ 0.7) of contributions from the pairs of signals (i) Complex II S3 3Fe4S and aconitase
3Fe4S, and (ii) Complex I N1b and N2 FeS clusters. N1b and N2 could not be deconvoluted and only the
overall contribution from N1b + N2 is given, whereas S3 and aconitase were deconvoluted by the use of two
temperatures (69). Computed spectra of the individual components were calculated with XSophe (Bruker
Biospin; (125, 126)) using spin Hamiltonian parameters from the literature (69-79), and computed spectra were
normalized for the intensity of ".dH (i.e. the first integral of the EPR absorption, or so-called "doubleintegrated spectrum") prior to fitting to the experimental data.

Results.
Recapitulation of mtDNA depletion in DGUOK rat. To evaluate the phenotype, three M2, four M1 and
six SS 8-week-old females were sacrificed and tissue harvested. DNA was extracted and subject to qPCR
evaluation using validated rat-specific primers, but otherwise as previously described (112). This method
demonstrates an approximately 90% reduction in hepatic mtDNA content (Figure 1). This reduction is similar
to the 80–90% reduction in hepatic mtDNA seen in humans with this disorder (112). Similarly, a 60–80%
reduction in splenic DNA content was observed (100). The situation was less clear in muscle; while M1 rats
exhibited about 60 % depletion in mtDNA, the mtDNA level in the M2 rat was indistinguishable from that in
wild-type. Consequently mtDNA content was assessed in sections of the same tissue that was used for
Histology, ETC and EPR assays. This demonstrates no significant difference in mtDNA content in skeletal
muscle, regardless of predominant oxidative fiber type (Table S1).
Pathology of the DGUOK rat. A pathological analysis was performed on 4 wild-type and 5 DGUOK rats
at approximately 11 months of age, including the histological evaluation of heart, lung, liver, spleen, kidney,
and muscle. H&E-stained sections of heart, lung, liver, spleen, and kidney revealed no apparent differences in
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the organ histology when comparing wild-type and DGUOK rats. Liver fibrosis was further evaluated using
Masson trichrome staining, which also showed no evident differences between wild-type and DGUOK livers. In
contrast, there were marked differences on oxidative enzyme staining when comparing the quadriceps
muscles of wild-type and DGUOK rats (Figure 2). While pathological differences were not apparent on H&E
staining, there were numerous fibers that showed negative staining on both cytochrome oxidase (COX) and
succinate dehydrogenase (SDH) stains (Figure 2). Large numbers (up to 20-30% of fibers) of these COX
negative/SDH negative fibers were seen in all DGUOK rats, whereas they were essentially absent in all of the
wild-type rat muscles examined.
Expression of respiratory chain complexes. Mitochondrial protein expression was found to be altered in
quadriceps muscle of the 11 month old DGUOK rat (Figure 3). Specifically, the data indicated that Complex I
was significantly under-expressed (54 % of wild-type; p = 0.05) and suggested that Complex III was also under
expressed (47 % of wild-type; p = 0.12). The expression levels of Complexes II, IV & V were unchanged in
DGUOK rat muscle. Varying, though generally low, amounts of an unidentified immunoreactive protein with Mr
 30 kDa were also observed.
Electron chain transport assays. Significantly lower activities for Complexes I, III and IV were observed
in DGUOK rat liver, corresponding to about 20 %, 7 % and 13 % of wild-type activity, respectively, whereas
Complex II activities were statistically indistinguishable (Figure 4, Table 1). In DGUOK muscle, the activities of
Complexes I and III were only 9 % and 20 % of wild-type, respectively, whereas Complex II and IV activities
were essentially indistinguishable.
EPR spectroscopy. The EPR spectra at 12 K of liver, quadriceps muscle and heart from wild-type and
DGUOK rats are shown in Figure 5. The signals are complex but some features are immediately identifiable
and are labeled a - k in Figure 5. Feature a at g' ~ 6 is due to high-spin ferriheme; b at g' ~ 4 is due largely to
Fe(III) in transferrin; a complex pattern extending upfield from c is due to Mn(II), which is prominent in liver but
much less so in quadriceps muscle and not detectable in heart, and overlaps the signals from the respiratory
chain iron sulfur clusters; the prominent feature at d is the so-called "g = 2.01" signal and is due to overlapping
signals from the oxidized 3Fe4S clusters of Complex II and oxidatively-damaged aconitase; the signal at e, the
so-called "g = 1.94" signal, is due to overlapping g2 resonances from reduced 2Fe2S and 4Fe4S clusters,
primarily those from Complex I; the signals at f are the g3 resonances from Complex I N4 4Fe4S (lower field)
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and Complex I N3 2Fe2S (higher field) and are overlaid on the highest field mI = 5/2 resonance of the mS = 1/2
manifold of S = 5/2 Mn(II) (the latter is not clear in trace A but much more pronounced in trace B); the
resonances labeled g are gx and gy of the rhombic high-spin ferriheme of catalase (88); the resonances around
h are due to low-spin ferriheme; feature i is the g1 (gx) resonance of low-spin heme a of Complex IV; and k
indicates the g1 (gx; lower field) and g3 (gz; higher field) resonances from the Rieske 2Fe2S cluster of Complex
II. The broad EPR absorption in the liver spectra from about 2000 G is largely due to rapid-passage of the
Mn(II) leading to an absorption-like signal that includes components from the mS = 3/2 and mS = 5/2 manifolds
(127), along with some contribution from CuA of Complex IV.
Visual inspection of the spectra provides some limited information. Mn(II) is clearly elevated in DGUOK
liver whereas the reduced Complex I FeS signals (e, f) are diminished. In DGUOK quadriceps muscle, the
Complex I FeS signals and the Complex III Rieske signals are markedly diminished compared to wild-type. In
both muscle and liver, the g = 2.01 signal (d) due to Complex II S3 and/or aconitase appears elevated in
DGUOK compared to wild-type. To further investigate this phenomenon, spectra were recorded at 40 K
(Figure 6) where the faster-relaxing S3 signal intensity is lowered relative to the more slowly relaxing
aconitase signal. In liver, the difference in intensity of the g = 2.01 signal persists and we assign this as being
due to a 25 % increase in the aconitase signal in DGUOK over wild-type. In quadriceps muscle at 40 K, the
DGUOK signal is now smaller than the wild-type signal, indicating that the difference at 12 K is due to elevated
amounts of oxidized Complex III S3 3Fe4S. Clear signals due to g1 (gx) of heme a of Complex IV were only
observed in heart. The signals in liver and quadriceps were much broader and suggestive of a distribution of gvalues; this resonance position of this signal was found to be very sensitive to mutations in bacterial
cytochrome c oxidase (128) and the apparent distribution of g1 values may reflect multiple environments in liver
mitochondria. In liver, the signal from transferrin was elevated and that from catalase was depressed.
Interestingly, no significant differences at all were observed between the EPR spectra of heart from wild-type
and DGUOK rats.
For quantitative information we turned to computer simulation of the spectra. Figure 7 shows the g ~ 2
region of the experimental spectra for liver (A, B), quadriceps muscle (E, F) and heart (I, J) from DGUOK and
wild-type rats. In each case, fits to the library of computed spectra were generated. As we are particularly
interested in the differences between wild-type and DGUOK, difference spectra (DGUOK minus wild-type) of
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the experimental data (C, G and K for liver, muscle and heart, respectively) and the computed fits (D and H for
liver and muscle; no significant difference was observed between the fits to wild-type and DGUOK heart) are
presented. The experimental and computed difference spectra match very well and details of the fits are given
in Table 2/Table S2. From the fit parameters, and using the dual temperature study to resolve the S3 and
aconitase 3Fe4S contributions, we calculated the fractional difference between the intensities of each of the
components in the DGUOK and wild-type tissues, and the significant results are summarized in Figure 8.

Discussion.
The aims of this work are to describe the DGUOK rat mitochondrial phenotype and evaluate it as a
model for mitochondrial disease, and to apply EPR spectroscopy of tissue to enable an understanding of what
happens at the electron level in tissue with mtDNA depletion. The DGUOK rat has a complex and tissuedependent mitochondrial phenotype. The DGUOK liver exhibited markedly lower mtDNA copy number, ~ 10 %
of wild-type. However, EPR showed that Complex I FeS clusters were present at least 50 % as much as in
wild-type, and signals from S1, S2, S3 and the Rieske FeS clusters indicated that Complexes II and III are
expressed at the same level as in wild-type. The observation that the four EPR-detectable FeS cluster signals
are depleted by the same amounts, despite very different redox potentials, and that signal intensities from both
the S1-S2 pair and the Rieske cluster are indistinguishable from wild-type suggests that (i) the lowered
Complex I signals are due to depressed expression or Fe incorporation, rather than an elevated redox potential,
and (ii) the depleted Complex I complement therefore provides sufficient electrons to load the electron transfer
chain. The aconitase 3Fe4S signal, a characteristic marker for oxidative stress (82), was elevated in DGUOK
liver. Also, Mn(II), which is present at high levels in wild-type liver and is proposed to be additionally generated
in response to oxidative stress (127), was doubled compared to wild-type. The activities of Complexes I, III and
IV in DGUOK liver were very depressed compared to wild-type, and by far more that can be accounted for by
expression levels. It is tempting to speculate that the oxidative stress identified by the aconitase and Mn(II)
EPR signals is either a cause or consequence of the additional Complex I, II and IV dysfunction in DGUOK
liver. The very low levels of Complexes III and IV activities explain the EPR observation that the electron
transfer chain remains electron-rich, and the redox potential maintained close to the NADH:NAD midpoint
potential, even though Complex I activity is also significantly depressed. The elevation of the EPR signal from
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transferrin may indicate some hemorrhaging, and the depression of the catalase signal also suggests some
disease or damage to the liver (129).
The mitochondrial phenotype in DGUOK quadriceps muscle is also complex. Consistent with muscle
evaluated in humans with severe disease, protein expression levels for Complexes I and III were also ~ 50 %
of wild-type, whereas Complexes II, IV and V were expressed at wild-type (108). However, in contrast to
humans with severe disease, the mtDNA copy numbers for wild-type and M2 DGUOK were similar across all
muscle groups [table S1]. This lack of difference in the muscle types may reflect variability in sampling, the
milder phenotype in the rats or an underlying correction in muscle tissue for example by de novo purine
synthesis or alternate salvage pathways. This data underscores the limited sensitivity of qPCR previously
described in human muscle (112) and emphasizes the need to consider evaluation of liver specifically for
depletion in this disease.
Consistent with protein expression levels, EPR of DGUOK quadriceps muscle indicated that Complex I
is present at  35 % of the wild-type level and Complex III at about 50 %. The EPR data for Complex II are
revealing. The S3 cluster signal was twice as intense as in wild-type, yet the S1 and S2 clusters were
diminished by a factor of two. This could indicate a catastrophic inability to correctly assemble Complex II or
incorporate S1 and S2 but this would be expected to essentially abolish activity, and the elevation of S3 would
require a doubling of Complex II expression. Neither phenomenon was observed. More likely, the changes in
S1, S2 and S3 reflect a Complex II that experiences a significantly more oxidizing redox potential than in wildtype mitochondria. This hypothesis is strongly supported by the very low Complex I electron transferring
activity compared to the downstream activities of Complexes II, III and IV. Therefore, Complex II is drained of
electrons and produces the EPR signature observed in DGUOK quadriceps muscle. This scenario also
explains the lack of markers for oxidative stress in the EPR signature of DGUOK muscle. In the absence of
Complex I activity, very few electrons enter the respiratory chain to begin with. Furthermore, the downstream
components are in a more oxidized state and thus are primed to receive any electrons that do enter the
respiratory chain, essentially acting as antioxidants. So, while Complex III dysfunction results in electron buildup and oxidative stress in DGUOK liver, the lack of activity of Complex I and downstream oxidation of
Complexes II - IV in muscle does not result in oxidative stress even though Complex III activity is as depressed
in muscle as it is in liver. The only EPR marker observed for Complex IV in this study, the heme a signal, was
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very weak and broad in muscle and was not significant in the fits. Nevertheless, visual examination suggests a
comparable signal in wild-type and DGUOK, consistent with the significant Complex IV activity. What remains
unclear is the reason(s) behind the low activities of Complexes I and III. Native PAGE provides no evidence for
subunit depletion, and EPR does not indicate oxidative stress.
In contrast to liver and quadriceps muscle, the heart in the DGUOK rat appears entirely unaffected. The
mtDNA copy numbers are normal and the EPR signals of wild-type and DGUOK heart are indistinguishable
themselves and very similar to wild-type quadriceps muscle. Large EPR signals from Complex I N3 and N4, a
large signal from Complex III Rieske 2Fe2S, a high ratio of the g = 1.94 and g = 2.01 signals, and a weak
signal from Complex IV heme a all indicate a very reducing environment that is consistent with an active
Complex I and a fully functioning respiratory chain that does not produce oxidative stress.
EPR is a unique tool in that it can interrogate the status of the mitochondrion at the time of freezing, in
unprocessed viable biological samples. First, it is clear that in both liver and quadriceps muscle, EPR identified
mitochondrial dysfunction in the DGUOK rat. Second, some mechanistic information on the DGUOK rat was
obtained. In liver, the EPR results indicated that the reduced electron transfer chain activity of Complexes I is
in part due to reduced expression but that the very low activity of Complex, III is not a consequence of reduced
expression or Fe incorporation as FeS clusters. The retention of the Complex III Rieske 2Fe2S EPR signal in
DGUOK liver indicates that Complex III is present at wild-type levels, incorporates the Rieske cluster, and
electrons can progress through the respiratory chain at least as far as the Rieske cluster. The reason for
Complex III inactivity remains unknown but appears to be downstream of the Rieske cluster. Oxidative stress
may be important, and two independent markers for oxidative stress were identified, elevated aconitase 3Fe4S
and Mn(II); two markers for liver damage were also identified, depressed catalase and elevated transferrin. In
quadriceps muscle, EPR provides complementary information to the activity assays. The lack of Complex I
activity and the EPR identification of oxidation of the three Complex II FeS clusters provides a rationale for the
lack of any EPR markers for oxidative stress in muscle. A knowledge of whether oxidative stress is a
consequence of mitochondrial disease, and in which tissues and why, is an important piece of information that
may inform therapy choices.

Conclusions.
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The DGUOK rat capitulates major biochemical features observed in humans with DGUOK deficiency,
specifically significantly reduced mtDNA content, reduced mitochondrial complex I, III and IV protein content
and enzymatic activity in frozen liver. EPR assessment of flash-frozen tissues has demonstrated dramatic
differences in the mitochondrial electron transport chain status in situ compared with wild-type animals. The
reproducibility and magnitude of these differences is encouraging given the relatively mild pathologic
differences seen in the animals. It suggests that EPR may be able to reliably distinguish individuals with
mitochondrial disease from distinct etiologies of muscle or liver disease in humans.
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1000 x Wild-type
activity  citrate
synthase activity

1000 x DGUOK
activity  citrate
synthase activity

Mann-Whitney
U test p-value

t-Test with
transformed data
p-value

LIVER
Complex I
Complex II
Complex III
Complex II - III
Complex IV

230.08 ± 18.81
991.9 ± 95.3
14.35 ± 0.80
430.1 ± 32.6
137.54 ± 11.69

47.64 ± 9.53
1291.6 ± 258.3
1.02 ± 0.20
129.3 ± 25.9
17.70 ± 3.54

0.008
0.522
0.008
0.029
0.014

0.002
0.250
0.001
0.012
0.002

MUSCLE
Complex I
Complex II
Complex III
Complex II -III
Complex IV

108.1 ± 8.25
278.1 ± 16.42
3.43 ± 0.48
263.7 ± 28.53
38.63 ± 5.60

9.73 ± 4.25
215.8 ± 18.41
0.70 ± 0.18
157.6 ± 15.36
53.93 ± 8.76

0.008
0.522
0.036
1.00
0.412

0.015
0.093
0.025
0.070
0.434

Table 1. Results of electron transport chain assays of Complexes I - IV from muscle and liver from wild-type and
DGUOK rats.
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EPR Signal

Liver
W/T

Liver
DGUOK
[ (%)]a
CuA
47 ± 13
44 ± 15
[NS]c
Heme a
200 ± 50 100 ± 60
[-50]
High-spin heme
116 ± 7
71 ± 9
[-39]
N1b + N2
26 ± 5
16 ± 5
[-39]
FeS N3
17 ± 8
8±5
[-53]
FeS N4
41 ± 8
20 ± 6
[-51]
All Complex I FeS 84 ± 12
44 ± 9
[-49]
S3 + Acn
10.8 ± 1.6 15 ± 2
[+37]
FeS S1
27 ± 10
29 ± 13
[NS]
FeS S2
ND
ND
S1 + S2
27 ± 10
29 ± 13
[NS]
Rieske FeS
99 ± 11
98 ± 12
[NS]
Mn(II)
295 ± 27 588 ± 32
[+99]

Muscle
W/T

Muscle
DGUOK
[ (%)]
13 ± 1
[+45]
ND

Heartb

31 ± 1
[-30]
28.2 ± 0.2 7.4 ± 0.5
[-74]
16 ± 1
5.5 ± 0.7
[-61]
33 ± 1
14 ± 1
[-59]
77 ± 1
26 ± 1
[-66]
1.3 ± 0.1
3.8 ± 0.1
[+192]
15 ± 1
8±1

183  3

ND
15 ± 1

60 ± 5
76 ± 7

9±1
ND
44 ± 1

37 ± 1
32 ± 3

ND
8±1
[-48]
18 ± 1
[-51]
20 ± 2
[-35]

Bennett et al

NDd
200 ± 30

111  1
38  4
108  4
257  6
17  1
16 ± 5

238 ± 5
ND

Table 2. Fitting parameters for the EPR signals from spectra of liver and muscle tissue from wild-type and DGUOK rats.
The absolute intensities of each species (or group of species) are shown for wild-type and DGUOK, along with the
percentage differences between DGUOK and wild-type intensities in brackets.
Footnotes. (a) Calculated as {[(DGUOK signal) - (wild-type signal)]  (wild-type signal)}  100. (b) Wild-type and
DGUOK heart were indistinguishable. (c) Not significant. (d) None detected.
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Figure 1. Absolute mtDNA content in DGUOK rats. The mtDNA copy numbers for eight week old M1 and M2
DGUOK knockout rats compared with wild-type (SS) rats. The error bars indicate standard deviations for n = 6 (SS), n =
4 (M1) and n = 3 (M2).
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Figure 2: Skeletal muscle pathology in 11 month old WT and DGUOK rats. Quadriceps muscles from DGUOK rats
display little differences on H&E staining in comparison to WT littermates. In contrast, staining for COX and SDH
reveals numerous fibers in DGUOK rat muscle that are negative for both COX and SDH, whereas no such fibers were
evident in WT rat muscle. The bar at the bottom, right corresponds to 200 m.
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Figure 3. Respiratory chain complex expression in DGUOK rat muscle. Western blots of mitochondrial electron
transport chain complexes I-V and GAPDH from stripped membranes of quadriceps muscle from 11 month old wild-type
and DGUOK rats are shown in the top panel. The results of quantitation of the respiratory chain complex bands are shown
below, normalized for GAPDH expression. The error bars indicate standard errors for n = 4.
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DGK activity (% of W/T)
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80
60
40
20
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CII
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CIII
Liver;

CIV
Muscle

Figure 4. Electron transport chain functional assays of Complexes I - IV. The functional activities of
Complexes I - IV from liver and quadriceps muscle of DGUOK rat are shown, normalized for mitochondrial content (as
citrate synthase activity) and expressed as percentages of activities from wild-type. Detailed results are given in Table 1
(or S1).
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Figure 5. 12 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat
liver; B, DGUOK rat liver; C, wild-type rat quadriceps muscle; D, DGUOK rat quadriceps muscle; E, wild-type rat heart;
and F, DGUOK rat heart. In each case, the sample completely filled the part of the EPR tube that occupied the active
region of the resonator. A & B shown x 1, C & D are shown x 2, and E & F shown x 0.5. Spectra were recorded at 12 K,
2.5 mW power. The lower-case labels identify specific signals in the spectra: (a) high-spin axial ferriheme g; (b)
transferrin non-heme Fe(III); (c) the mI = 5/2 line at the low-field extremity of the six-line Mn(II) hyperfine pattern; (d)
overlapping signals from aconitase and S3 [3Fe4S] clusters; (e) overlapping g2 resonances from Complex I [2Fe2S] and
[4Fe4S] clusters; (f) resolved g3 resonances from N4 and N3 clusters; (g) high-spin catalase gx and gy lines; (h) low-spin
catalase resonances; (i) heme a g1; and (k) Rieske [2Fe2S] cluster g1 and g3 resonances.
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Figure 6. 40 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat
liver (solid line) and DGUOK rat liver (dashed line); and B, wild-type rat quadriceps muscle (solid line) and DGUOK rat
muscle (dashed line). Spectra were recorded at 40 K, 2.5 mW power.
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Figure 7. Quantitative analysis of the 12 K EPR signals from wild-type and DGUOK rat tissues. Traces A, B, E, F, I
and J show the g' ~ 2 region of the EPR spectra of A, wild-type rat liver; B, DGUOK rat liver; E, wild-type rat quadriceps
muscle; F, DGUOK rat quadriceps muscle; I, wild-type rat heart; and J, DGUOK rat heart. Trace C is the difference
spectrum obtained by subtraction of A from B, and is shown multiplied by a factor of two; likewise, G = 2(F - E) and K
= 2(J - I). Trace D is a theoretical simulation of C generated by the subtraction of fits of A and B to model spectra of the
paramagnetic species likely to be observed in the mitochondrion. Fitting parameters are presented in Table 2 (or S2).
Similarly, trace H is a simulation of J from fits to E and F. No attempt was made to simulate K, as no significant
differences were observed between fits to I and J.
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Figure 8. Summary of EPR of DGUOK rat liver and muscle. A comparison of signal intensities is shown for some of
the respiratory complex redox centers in liver and muscle from the DGUOK and wild-type rat. The standard errors were
calculated from those of the fit parameters, presented in Table 2 (or S2).
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Table S1
In contrast to liver (n=5), mtDNA content in muscle tissue from 4 Wild Type (Dahl/SS) rats compared with 4
DGUOK M2 rats demonstrates no significant difference.

SOLEUS MUSCLE
GASTROCNEMIUS MUSCLE
TRICEP MUSCLE
DELTOID MUSCLE
LIVER

WILD TYPE RAT
1036
910
1270
1043
1981

DGUOK M2 RAT
710
571
418
1043
187
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Abstract.
A novel rat model for a well-characterized human mitochondrial disease, mitochondrial DNA depletion
syndrome with associated deoxyguanosine kinase (DGUOK) deficiency, is described. The rat model
recapitulates the pathologic and biochemical signatures of the human disease. The application of electron
paramagnetic (spin) resonance (EPR) spectroscopy to the identification and characterization of respiratory
chain abnormalities in the mitochondria from freshly frozen tissue of the mitochondrial disease model rat is
introduced. EPR is shown to be a sensitive technique for detecting mitochondrial functional abnormality in situ
and, here, is particularly useful in characterizing the redox state changes and oxidative stress that can result
from depressed expression and/or diminished specific activity of the distinct respiratory chain complexes. As
EPR requires no sample preparation or non-physiological reagents, it provides information on the status of the
mitochondrion as it was in the functioning state. On its own, this information is of use in identifying respiratory
chain dysfunction; in conjunction with other techniques, the information from EPR shows how the respiratory
chain is affected at the molecular level by the dysfunction. It is proposed that EPR has a role in mechanistic
pathophysiological studies of mitochondrial disease and strong potential as an additional diagnostic tool.

Keywords.
DGUOK, redox, oxidative, stress, mtDNA depletion, pathology

Graphical abstract.
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Highlights.
EPR demonstrates marked signal changes in a rat with DGUOK deficiency that resembles human disease

Abbreviations.
COX, cytochrome oxidase; M2, deoxyguanosine kinase-deficient rat model; DGUOK, deoxyguanosine kinase;
EPR (ESR), electron paramagnetic (spin) resonance; FeS, iron-sulfur (cluster); H&E, hematoxylin and eosin;
MD, mitochondrial disease; MDS, mitochondrial DNA depletion syndrome; MPV17 mitochondrial inner
membrane protein; mtDNA, mitochondrial DNA; NADH, reduced nicotinamide adenine dinucleotide; POLG,
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DNA polymerase γ; SDH, succinate dehydrogenase; TWINKLE, a mitochondrial DNA helicase encoded by
chromosome 10, open reading frame 2 (also known as C10orf2)
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Introduction.
Mitochondrial disease (MD) occurs where depletion of mitochondrial DNA (mtDNA) or mutations in
mtDNA and/or nuclear DNA (nDNA) lead to altered mitochondrial function.(1-4) Altered activities of Complexes
I – V have been identified and physiological consequences of mitochondrial respiratory chain defects include
reduced metabolic capacity, reduced ATP synthesis, and increased oxidative and nitrosative stress.(5-15)
Symptoms of MD are manifold and include weakness (from central nervous system, peripheral nerve, and/or
skeletal muscle disease), pain, intolerance of some general anesthetics and anti-epileptic drugs,
gastrointestinal disorders, ophthalmoplegia and/or visual failure, failure to thrive, cardiac and respiratory
disease, liver disease, diabetes, seizures, sensorineural hearing loss, mental retardation, dementia, movement
disorders, increased susceptibility to infection, and pregnancy loss.(1, 2, 16-38) Establishing diagnoses and
understanding the pathophysiology of mitochondrial disease (MD) has proven extremely challenging because
of the extraordinary range of clinical symptoms and testing abnormalities (39). MD is often suspected in early
childhood from clinical differential diagnosis of patients with diseases involving the brain, muscle, or liver.
Traditional methods for diagnosing MD include clinical presentation, family history, pathology, metabolic
profiling, enzyme activity levels, electrophysiology, magnetic resonance imaging (MRI) of brain and magnetic
resonance spectroscopy (MRS) of metabolites, and mtDNA analysis (3, 7, 31, 40-53). Additional indicators
include observation of mitochondrial proliferation, abnormalities on muscle histology (e.g., ragged red fibers or
succinate dehydrogenase-positive fibers) (41, 54), and abnormalities in electron microscopy (46, 55). However,
muscle histology may be normal despite the presence of biochemical abnormalities in the tissue. The
determination of whether MD is present in a given patient can be extremely complex, given that (i)
mitochondrial function can be secondarily affected due to the disease processes in non-mitochondrial diseases,
(ii) there can be extensive variability in the distribution of abnormal mitochondria within an individual patient,
allowing a “false negative” testing profile to occur when tissues with mitochondrial abnormalities are not tested,
and (iii) there are no uniform, definitive pathological abnormalities that distinguish all MD patients from patients
with other disorders. Diagnosis may ultimately rely on the application of diagnostic algorithms to predict the
likelihood of MD (56, 57) but MD is currently an under-diagnosed disease (4, 58-64).
Mechanistic information on MD has largely arisen from mitochondrial electron transport chain
component activity assays on the components, isolated from their native matrix from fresh or frozen tissue, or
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from cultured cells. These assays are, like most clinical biochemical assays, performed under non-physiologic
basal conditions and with very different substrate concentrations than are seen in-vivo. Complex interactions
between the substrates of these assays and other cellular components can lead to erroneous results (65)
though these problems can, in principle be, overcome with careful isolation of proteins or in-gel assays. Assays
of activities outside of the intact mitochondrial environment cannot identify defects in mitochondrial membrane
potential or coupling. In clinical practice, it has been found that the methodological variations, limitations and
difficulties associated with the use of respiratory chain functional assays as a diagnostic method for MD has
led to massive inter-laboratory variability in results (66). In alternative approaches, substrates are added to
whole cells or isolated mitochondrial preparations, and either oxygen consumption or ATP generation is
measured [reviewed in (67)]. While recognized as the current standard for mitochondrial testing there are,
again, significant limitations. Most apparent is the requirement for viable functioning mitochondria, requiring cell
preparation or mitochondrial isolation and testing to be carried out temporally, and therefore geographically,
proximate to the biopsy. The process of isolating mitochondria from native tissue risks damage and places the
organelle outside of a truly physiologic condition. Conversely, whole cell assays require permeabilization of the
cell to the substrates and transport to the mitochondria. The potentially limited ability to get reagents to the site
of action can lead to a loss of sensitivity and specificity. In all of the currently employed assays, the
mitochondrial function is not assessed in its native-organ context in the human and the need persists for an
assay that measures the functional ability of mitochondria in an intact tissue preserved in a state as close as
possible to that in situ.
Electron paramagnetic (spin) resonance (EPR, ESR) is a technique that can provide unique insight into
mitochondrial status. EPR detects and characterizes free radicals and many transition metal ions and clusters
in biological systems by measuring the magnetic field dependence of the absorption of microwave radiation at
a given frequency by the unpaired electrons residing in these species (68). The mitochondrial respiratory chain
Complexes I - IV are particularly rich in transition metal-containing redox centers, with a complement of 21
centers that include heme iron, copper, and [2Fe2S], [3Fe4S] and [4Fe4S] iron sulfur (FeS) clusters. Up to 18
of these adopt EPR-detectable paramagnetic states in native mitochondria and are readily observed at
temperatures close to liquid helium (10 - 40 K) (69). The spin-Hamiltonian parameters, midpoint potentials and
relaxation behavior of these centers have been reasonably well characterized (69-87), along with some other
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tissue-specific signals from transferrin, ceruloplasmin, and catalase (88-90). Specific applications of EPR to
mitochondria have included detection of an irreversible deficiency in Complex I FeS clusters in iron -deficient
rats (91), heme-nitrosyl in substantia nigra of Parkinson's diseased brain (92), chromium-dependent inhibition
of Complexes I & II and aconitase (93), cardio- and neuro-protection against doxorubicin (80), prophylaxis
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a Parkinson's mouse model (82), the differential
sensitivity of aconitase and FeS clusters from Complexes I & III to oxidative and nitrosative stress in heart (94),
and the sensitivity of Complex III FeS clusters in aging heart to ischemia (95). However, despite these
successes in mechanistic studies, the authors are unaware of any direct application of EPR for functional
pathophysiologic studies in humans or whole animal models with primary mitochondrial disease; the closest
analog is a study in which a comparison of EPR signals from muscle biopsies of sepsis patients indicated
significant depletion of Complex I FeS signals in those who died compared to survivors (86, 96).
One group of MD that has been recently well-characterized and suggests itself as a promising model
for evaluation of new pathophysiologic methodologies is the mitochondrial DNA (mtDNA) depletion syndromes
(MDS). MDS comprises a genetically and clinically heterogeneous group of autosomal recessive diseases
characterized by a reduction in tissue-specific mtDNA copy number. This reduction is a result of molecular
defects in either the genes responsible for mtDNA biogenesis, or those required for the maintenance of
deoxynucleotide pools or mtDNA integrity (97-99). The loss of mtDNA can lead to a variety of clinical
presentations that are dependent on the gene involved and the nature of the mutation. Depletion of mtDNA is
the most common cause of multi-systemic oxidative phosphorylation defects (100), with deoxyguanosine
kinase (DGUOK) deficiency being the most frequent cause. Death commonly results from liver failure (26, 97,
101, 102), which may occur in the context of natural disease progression, exposure to sodium valproate (103105) or complications of viral infections such as influenza (55, 106). Less severe attenuation of DGUOK
function may result in a susceptibility to isolated liver failure (97, 107, 108) or a myopathic presentation of
DGUOK deficiency (109). Some cases with milder mutations have required liver transplantation, with its
attendant complications, and may subsequently develop myopathy (97, 108). Over the preceding 5 years, we
have developed an accurate method for assay of tissue-specific mitochondrial DNA content using quantitative
real-time polymerase chain reaction (qPCR) that has led to accurate retrospective modeling and prospective
diagnosis of patients with hepatic mtDNA depletion (55, 110-116). This is accepted as the clinical standard for
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diagnosis of mtDNA depletion (54). The development of a robust diagnosis for MDS and the detailed
characterization of DGUOK deficiency, in particular, suggested to us that an animal model of DGUOK
deficiency would be of great value in developing and evaluating the potential of new diagnostic and
pathophysiologic techniques for MD.
In the present work, we aim to introduce EPR of tissue samples at cryogenic temperatures as a
mechanistic tool for MD. We have developed a rat model of DGUOK deficiency (referred to by the trivial name
"DGUOK") that exhibits characteristic biomarkers, and we have applied standard biochemical and pathological
tests along with EPR. The goals of this work are to characterize the DGUOK rat in terms of mitochondrial
dysfunction and pathological outcome, and to evaluate EPR as a new and additional technique in an integrated
characterization of MD.

Materials and Methods.
The DGUOK rat model of DGUOK deficiency. Previously described zinc-finger nuclease (ZFN)
technology was employed (117, 118). A preferred binding/cutting site of
GTCGGTTCCTTCTGCgtagacTCCGAGCGTCTTTCCG was identified from a clinically relevant transcript of
DGUOK and the appropriate ZFN was obtained from Sigma Aldrich (CompoZr Custom ZFN Service). This was
injected into the pronucleus of a fertilized one-cell embryo. These microinjected embryos were then implanted
into a “pseudo-pregnant” recipient female rat. This resulted in the generation of four characterized DGUOK rat
knockout lines named SSdguokM1 SSdguokM2 SSdguokM3and SSdguokM4. Because of the rare potential for an off-target
effect, where ZFNs cause double-strand breaks and mutations at undesired loci, we backcrossed and bred
homozygote animals from these two lines (117). The “M1” line has a 31 base pair deletion after amino acid six
leading to a premature stop codon, i.e., a polypeptide with 34 amino acids (the first 6 from the original protein
sequence and 28 from the missense). Similarly, the “M2” line has a 37 base pair amino acid deletion after
amino acid six. This frame-shift mutation would lead to a 42 amino acid polypeptide with only the first 6 amino
acids consistent with the original protein sequence.
The M3 line had a net 57bp frameshift deletion in exon 1 including the initiation codon which is predicted
to lead to the use of an alternate start codon in exon 1 with a 5’ truncated protein devoid of the mitochondrial
targeting sequence. The M4 line had an in-frame deletion of 9 nucleotides in the targeting sequence. This
8
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strain does not have hepatic mtDNA depletion and, because of the adequacy of the first two models, was not
further characterized.
The generation of the animal model and all subsequent animal experiments were performed under
approved Animal Use Application by the Institutional Animal Care and Use Committee (IACUC) of the Medical
College of Wisonsin (protocols 2214 and 1764, respectively).
mtDNA assay. Real time analysis was performed as previously published and validated in humans (55,
97, 112) using rat specific primers. DNA was extracted using Qiagen Blood Core Kit #158389 and quantified
using the Quant-iT PicoGreen double stranded DNA kit (Invitrogen) and a Varioskan plate reader (Thermo
Fisher) in 96 well format. DNA is diluted to a concentration falling with in efficiency range of the assay 0.125 -4
ng/l. qPCR was carried out on 10 l samples, each containing between 0.35 and 12 ng of extracted DNA, 5
pmol of each forward and reverse primer, and 5 l iTAQ SYBR Green Supermix with ROX (BioRad). The
mitochondrial genome-targeted rat-specific primers used were tRNALeu F: GGTTATTAGGGTGGCAGAGC
and tRNALeu R:GGAAGGCCATGGCAATTAAG. Nuclear primers, targeted to the ActB coding region, were
ActB F:TACCACTGGCATTGTGATGG and ActB R: ACGCTCGGTCAGGATCTTC. The Basic Local Alignment
Search Tool (National Center for Biotechnology Information) was used to show that primers hybridized to
unique sequences in Rattus norvegicus. The real-time qPCR cycling conditions were (i) 50°C for 2 min, (ii)
95°C for 10 min, (iii) 45 cycles of 15 seconds at 95°C, and (iv) a combined 62°C anneal/extension for 30
seconds. Upon completion of 45 cycles, a pre-programmed dissociation step was carried out by one cycle of
95°C for 15 seconds, 50°C for 15 seconds and 95°C for 15 seconds. Real-time fluorescence was measured
and analyzed on a 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA) using SDS
V2.3 software. All samples were assayed in triplicate. The relative mtDNA copy number was determined from
the threshold difference between the averages of each set of triplicate reactions.
Histology. A portion of each heart, lung, liver, spleen, and kidney from 4 wild-type SS rats and 5
SSdguokM2DGUOK rats at 11 months of age was fixed in formalin for histological analysis. Fixed tissue was
paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) using standard techniques. To
evaluate possible liver fibrosis, sections of liver were also stained using Masson trichrome stain using standard
techniques. For evaluation of muscle pathology, a quadriceps muscle from each animal was frozen in
isopentane at -78.5 C, and 8 m cryosections were stained for H&E, Gomori trichrome, reduced nicotinamide
9
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adenine dinucleotide (NADH), cytochrome oxidase (COX), and succinate dehydrogenase (SDH) using
standard techniques.
Protein immunoblot (western blot). Protein homogenates prepared from the quadriceps muscle were
evaluated for mitochondrial electron transport chain complex expression using standard western blot
techniques (119). Transferred proteins were probed with a MitoProfile Total OXPHOS Blue Native WB
Antibody Cocktail (MitoSciences #MS603, Abcam, Cambridge, MA), which includes antibodies against
mitochondrial respiratory chain complexes I-V, and visualized using enhanced chemiluminescence.
Quantification was performed using ImageJ version 1.44p and statistics were evaluated using Student’s t-test.
Electron transport chain activity assay. Electron transport chain activity assays were carried out on
frozen rat muscle and liver (n = 6 for controls and n = 5 for DGUOK rats) according to protocols previously
described in detail (120, 121) with the modification that the linear initial velocity in the first minute was
determined for Complex III, instead of a formal rate constant, due to the lower activity compared to Complexes
I, II and IV. The activities of Complexes I - IV were normalized for mitochondrial content by dividing by citrate
synthase activity. The results of electron transport chain activity assays are not normally distributed but
become so after transformation to their natural logarithms. Results are expressed as average values and the
standard error of the mean. Significance is expressed by the non-parametric Mann-Whitney U test on the raw
data and by Student's t-test of the logarithmically transformed data. Blue native PAGE analysis with in-gel
activity staining was carried out as previously described (121-123). This allowed the identification of decreased
synthesis of mitochondrial subunits (124).
EPR spectroscopy. Fresh tissue samples for EPR were rapidly extruded into 3 mm diameter EPR tubes
and frozen in liquid nitrogen within 90 s of harvest (we have found that tissue can be frozen much more rapidly
than dilute aqueous solutions and with much reduced risk of the EPR tube breaking). Samples entirely filled
the active length of the EPR resonator. EPR spectra were recorded on a Bruker EleXsys E600 spectrometer
equipped with a Super-X microwave bridge with integrated microwave counter, an ER4112SHQ resonant
cavity operating at 9.38 GHz, and an Oxford Instruments ESR900 helium flow cryostat and ITC503
temperature controller. Spectra were recorded with 10 G magnetic field modulation at 100 kHz and this
modulation amplitude determined the spectral resolution. Microwave powers and temperatures are given in the
figure legends. Scans of 4096 points, 8000 G field envelope and 3 min duration were averaged over 60 - 180
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min to provide the final spectrum. A background spectrum collected on frozen water was subtracted from rat
tissue spectra. Experimental spectra were modeled by fitting a library of computed spectra corresponding to
the mitochondrial respiratory chain centers and the [3Fe4S] cluster of aconitase (69), using a LevenbergMarquardt algorithm to minimize 2 (IGOR Pro v. 6.32A, Wavemetrics, Lake Oswego, OR). The contributions
of each component were constrained to  0. Correlation matrices indicated strong interdependencies
(correlation coefficients ~ 0.7) of contributions from the pairs of signals (i) Complex II S3 3Fe4S and aconitase
3Fe4S, and (ii) Complex I N1b and N2 FeS clusters. N1b and N2 could not be deconvoluted and only the
overall contribution from N1b + N2 is given, whereas S3 and aconitase were deconvoluted by the use of two
temperatures (69). Computed spectra of the individual components were calculated with XSophe (Bruker
Biospin; (125, 126)) using spin Hamiltonian parameters from the literature (69-79), and computed spectra were
normalized for the intensity of ".dH (i.e. the first integral of the EPR absorption, or so-called "doubleintegrated spectrum") prior to fitting to the experimental data.

Results.
Recapitulation of mtDNA depletion in DGUOK rat. To evaluate the phenotype, three M2, four M1 and
six SS 8-week-old females were sacrificed and tissue harvested. DNA was extracted and subject to qPCR
evaluation using validated rat-specific primers, but otherwise as previously described (112). This method
demonstrates an approximately 90% reduction in hepatic mtDNA content (Figure 1). This reduction is similar
to the 80–90% reduction in hepatic mtDNA seen in humans with this disorder (112). Similarly, a 60–80%
reduction in splenic DNA content was observed (100). The situation was less clear in muscle; while M1 rats
exhibited about 60 % depletion in mtDNA, the mtDNA level in the M2 rat was indistinguishable from that in
wild-type. Consequently mtDNA content was assessed in sections of the same tissue that was used for
Histology, ETC and EPR assays. This demonstrates no significant difference in mtDNA content in skeletal
muscle, regardless of predominant oxidative fiber type (Table S1).
Pathology of the DGUOK rat. A pathological analysis was performed on 4 wild-type and 5 DGUOK rats
at approximately 11 months of age, including the histological evaluation of heart, lung, liver, spleen, kidney,
and muscle. H&E-stained sections of heart, lung, liver, spleen, and kidney revealed no apparent differences in
11
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the organ histology when comparing wild-type and DGUOK rats. Liver fibrosis was further evaluated using
Masson trichrome staining, which also showed no evident differences between wild-type and DGUOK livers. In
contrast, there were marked differences on oxidative enzyme staining when comparing the quadriceps
muscles of wild-type and DGUOK rats (Figure 2). While pathological differences were not apparent on H&E
staining, there were numerous fibers that showed negative staining on both cytochrome oxidase (COX) and
succinate dehydrogenase (SDH) stains (Figure 2). Large numbers (up to 20-30% of fibers) of these COX
negative/SDH negative fibers were seen in all DGUOK rats, whereas they were essentially absent in all of the
wild-type rat muscles examined.
Expression of respiratory chain complexes. Mitochondrial protein expression was found to be altered in
quadriceps muscle of the 11 month old DGUOK rat (Figure 3). Specifically, the data indicated that Complex I
was significantly under-expressed (54 % of wild-type; p = 0.05) and suggested that Complex III was also under
expressed (47 % of wild-type; p = 0.12). The expression levels of Complexes II, IV & V were unchanged in
DGUOK rat muscle. Varying, though generally low, amounts of an unidentified immunoreactive protein with Mr
 30 kDa were also observed.
Electron chain transport assays. Significantly lower activities for Complexes I, III and IV were observed
in DGUOK rat liver, corresponding to about 20 %, 7 % and 13 % of wild-type activity, respectively, whereas
Complex II activities were statistically indistinguishable (Figure 4, Table 1). In DGUOK muscle, the activities of
Complexes I and III were only 9 % and 20 % of wild-type, respectively, whereas Complex II and IV activities
were essentially indistinguishable.
EPR spectroscopy. The EPR spectra at 10 K12 K of liver, quadriceps muscle and heart from wild-type
and DGUOK rats are shown in Figure 5. The signals are complex but some features are immediately
identifiable and are labeled a - k in Figure 5. Feature a at g' ~ 6 is due to high-spin ferriheme; b at g' ~ 4 is due
largely to Fe(III) in transferrin; a complex pattern extending upfield from c is due to Mn(II), which is prominent in
liver but much less so in quadriceps muscle and not detectable in heart, and overlaps the signals from the
respiratory chain iron sulfur clusters; the prominent feature at d is the so-called "g = 2.01" signal and is due to
overlapping signals from the oxidized 3Fe4S clusters of Complex II and oxidatively-damaged aconitase; the
signal at e, the so-called "g = 1.94" signal, is due to overlapping g2 resonances from reduced 2Fe2S and
4Fe4S clusters, primarily those from Complex I; the signals at f are the g3 resonances from Complex I N4
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4Fe4S (lower field) and Complex I N3 2Fe2S (higher field) and are overlaid on the highest field mI = 5/2
resonance of the mS = 1/2 manifold of S = 5/2 Mn(II) (the latter is not clear in trace A but much more pronounced
in trace B); the resonances labeled g are gx and gy of the rhombic high-spin ferriheme of catalase (88); the
resonances around h are due to low-spin ferriheme; feature i is the g1 (gx) resonance of low-spin heme a of
Complex IV; and k indicates the g1 (gx; lower field) and g3 (gz; higher field) resonances from the Rieske 2Fe2S
cluster of Complex II. The broad EPR absorption in the liver spectra from about 2000 G is largely due to rapidpassage of the Mn(II) leading to an absorption-like signal that includes components from the mS = 3/2 and mS =
5

/2 manifolds (127), along with some contribution from CuA of Complex IV.
Visual inspection of the spectra provides some limited information. Mn(II) is clearly elevated in DGUOK

liver whereas the reduced Complex I FeS signals (e, f) are diminished. In DGUOK quadriceps muscle, the
Complex I FeS signals and the Complex III Rieske signals are markedly diminished compared to wild-type. In
both muscle and liver, the g = 2.01 signal (d) due to Complex II S3 and/or aconitase appears elevated in
DGUOK compared to wild-type. To further investigate this phenomenon, spectra were recorded at 40 K
(Figure 6) where the faster-relaxing S3 signal intensity is lowered relative to the more slowly relaxing
aconitase signal. In liver, the difference in intensity of the g = 2.01 signal persists and we assign this as being
due to a 25 % increase in the aconitase signal in DGUOK over wild-type. In quadriceps muscle at 40 K, the
DGUOK signal is now smaller than the wild-type signal, indicating that the difference at 10 K12 K is due to
elevated amounts of oxidized Complex III S3 3Fe4S. Clear signals due to g1 (gx) of heme a of Complex IV
were only observed in heart. The signals in liver and quadriceps were much broader and suggestive of a
distribution of g-values; this resonance position of this signal was found to be very sensitive to mutations in
bacterial cytochrome c oxidase (128) and the apparent distribution of g1 values may reflect multiple
environments in liver mitochondria. In liver, the signal from transferrin was elevated and that from catalase was
depressed. Interestingly, no significant differences at all were observed between the EPR spectra of heart from
wild-type and DGUOK rats.
For quantitative information we turned to computer simulation of the spectra. Figure 7 shows the g ~ 2
region of the experimental spectra for liver (A, B), quadriceps muscle (E, F) and heart (I, J) from DGUOK and
wild-type rats. In each case, fits to the library of computed spectra were generated. As we are particularly
interested in the differences between wild-type and DGUOK, difference spectra (DGUOK minus wild-type) of
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the experimental data (C, G and K for liver, muscle and heart, respectively) and the computed fits (D and H for
liver and muscle; no significant difference was observed between the fits to wild-type and DGUOK heart) are
presented. The experimental and computed difference spectra match very well and details of the fits are given
in Table 2/Table S2. From the fit parameters, and using the dual temperature study to resolve the S3 and
aconitase 3Fe4S contributions, we calculated the fractional difference between the intensities of each of the
components in the DGUOK and wild-type tissues, and the significant results are summarized in Figure 8.

Discussion.
The aims of this work are to describe the DGUOK rat mitochondrial phenotype and evaluate it as a
model for mitochondrial disease, and to apply EPR spectroscopy of tissue to enable an understanding of what
happens at the electron level in tissue with mtDNA depletion. The DGUOK rat has a complex and tissuedependent mitochondrial phenotype. The DGUOK liver exhibited markedly lower mtDNA copy number, ~ 10 %
of wild-type. However, EPR showed that Complex I FeS clusters were present at least 50 % as much as in
wild-type, and signals from S1, S2, S3 and the Rieske FeS clusters indicated that Complexes II and III are
expressed at the same level as in wild-type. The observation that the four EPR-detectable FeS cluster signals
are depleted by the same amounts, despite very different redox potentials, and that signal intensities from both
the S1-S2 pair and the Rieske cluster are indistinguishable from wild-type suggests that (i) the lowered
Complex I signals are due to depressed expression or Fe incorporation, rather than an elevated redox potential,
and (ii) the depleted Complex I complement therefore provides sufficient electrons to load the electron transfer
chain. The aconitase 3Fe4S signal, a characteristic marker for oxidative stress (82), was elevated in DGUOK
liver. Also, Mn(II), which is present at high levels in wild-type liver and is proposed to be additionally generated
in response to oxidative stress (127), was doubled compared to wild-type. The activities of Complexes I, III and
IV in DGUOK liver were very depressed compared to wild-type, and by far more that can be accounted for by
expression levels. It is tempting to speculate that the oxidative stress identified by the aconitase and Mn(II)
EPR signals is either a cause or consequence of the additional Complex I, II and IV dysfunction in DGUOK
liver. The very low levels of Complexes III and IV activities explain the EPR observation that the electron
transfer chain remains electron-rich, and the redox potential maintained close to the NADH:NAD midpoint
potential, even though Complex I activity is also significantly depressed. The elevation of the EPR signal from
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transferrin may indicate some hemorrhaging, and the depression of the catalase signal also suggests some
disease or damage to the liver (129).
The mitochondrial phenotype in DGUOK quadriceps muscle is also complex. Consistent with muscle
evaluated in humans with severe disease, protein expression levels for Complexes I and III were also ~ 50 %
of wild-type, whereas Complexes II, IV and V were expressed at wild-type (108). However, in contrast to
humans with severe disease, the mtDNA copy numbers for wild-type and M2 DGUOK were similar across all
muscle groups [table S1]. This lack of difference in the muscle types may reflect variability in sampling, the
milder phenotype in the rats or an underlying correction in muscle tissue for example by de novo purine
synthesis or alternate salvage pathways. This data underscores the limited sensitivity of qPCR previously
described in human muscle (112) and emphasizes the need to consider evaluation of liver specifically for
depletion in this disease.
Consistent with protein expression levels, EPR of DGUOK quadriceps muscle indicated that Complex I
is present at  35 % of the wild-type level and Complex III at about 50 %. The EPR data for Complex II are
revealing. The S3 cluster signal was twice as intense as in wild-type, yet the S1 and S2 clusters were
diminished by a factor of two. This could indicate a catastrophic inability to correctly assemble Complex II or
incorporate S1 and S2 but this would be expected to essentially abolish activity, and the elevation of S3 would
require a doubling of Complex II expression. Neither phenomenon was observed. More likely, the changes in
S1, S2 and S3 reflect a Complex II that experiences a significantly more oxidizing redox potential than in wildtype mitochondria. This hypothesis is strongly supported by the very low Complex I electron transferring
activity compared to the downstream activities of Complexes II, III and IV. Therefore, Complex II is drained of
electrons and produces the EPR signature observed in DGUOK quadriceps muscle. This scenario also
explains the lack of markers for oxidative stress in the EPR signature of DGUOK muscle. In the absence of
Complex I activity, very few electrons enter the respiratory chain to begin with. Furthermore, the downstream
components are in a more oxidized state and thus are primed to receive any electrons that do enter the
respiratory chain, essentially acting as antioxidants. So, while Complex III dysfunction results in electron build up and oxidative stress in DGUOK liver, the lack of activity of Complex I and downstream oxidation of
Complexes II - IV in muscle does not result in oxidative stress even though Complex III activity is as depressed
in muscle as it is in liver. The only EPR marker observed for Complex IV in this study, the heme a signal, was
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very weak and broad in muscle and was not significant in the fits. Nevertheless, visual examination suggests a
comparable signal in wild-type and DGUOK, consistent with the significant Complex IV activity. What remains
unclear is the reason(s) behind the low activities of Complexes I and III. Native PAGE provides no evidence for
subunit depletion, and EPR does not indicate oxidative stress.
In contrast to liver and quadriceps muscle, the heart in the DGUOK rat appears entirely unaffected. The
mtDNA copy numbers are normal and the EPR signals of wild-type and DGUOK heart are indistinguishable
themselves and very similar to wild-type quadriceps muscle. Large EPR signals from Complex I N3 and N4, a
large signal from Complex III Rieske 2Fe2S, a high ratio of the g = 1.94 and g = 2.01 signals, and a weak
signal from Complex IV heme a all indicate a very reducing environment that is consistent with an active
Complex I and a fully functioning respiratory chain that does not produce oxidative stress.
EPR is a unique tool in that it can interrogate the status of the mitochondrion at the time of freezing, in
unprocessed viable biological samples. First, it is clear that in both liver and quadriceps muscle, EPR identified
mitochondrial dysfunction in the DGUOK rat. Second, some mechanistic information on the DGUOK rat was
obtained. In liver, the EPR results indicated that the reduced electron transfer chain activity of Complexes I is
in part due to reduced expression but that the very low activity of Complex, III is not a consequence of reduced
expression or Fe incorporation as FeS clusters. The retention of the Complex III Rieske 2Fe2S EPR signal in
DGUOK liver indicates that Complex III is present at wild-type levels, incorporates the Rieske cluster, and
electrons can progress through the respiratory chain at least as far as the Rieske cluster. The reason for
Complex III inactivity remains unknown but appears to be downstream of the Rieske cluster. Oxidative stress
may be important, and two independent markers for oxidative stress were identified, elevated aconitase 3Fe4S
and Mn(II); two markers for liver damage were also identified, depressed catalase and elevated transferrin. In
quadriceps muscle, EPR provides complementary information to the activity assays. The lack of Complex I
activity and the EPR identification of oxidation of the three Complex II FeS clusters provides a rationale for the
lack of any EPR markers for oxidative stress in muscle. A knowledge of whether oxidative stress is a
consequence of mitochondrial disease, and in which tissues and why, is an important piece of information that
may inform therapy choices.

Conclusions.
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The DGUOK rat capitulates major biochemical features observed in humans with DGUOK deficiency,
specifically significantly reduced mtDNA content, reduced mitochondrial complex I, III and IV protein content
and enzymatic activity in frozen liver. EPR assessment of flash-frozen tissues has demonstrated dramatic
differences in the mitochondrial electron transport chain status in situ compared with wild-type animals. The
reproducibility and magnitude of these differences is encouraging given the relatively mild pathologic
differences seen in the animals. It suggests that EPR may be able to reliably distinguish individuals with
mitochondrial disease from distinct etiologies of muscle or liver disease in humans.
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Activity assayed
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1000 x Wild-type
activity  citrate
synthase activity

1000 x DGUOK
activity  citrate
synthase activity

Mann-Whitney
U test p-value

t-Test with
transformed data
p-value

LIVER
Complex I
Complex II
Complex III
Complex II - III
Complex IV

230.08 ± 18.81
991.9 ± 95.3
14.35 ± 0.80
430.1 ± 32.6
137.54 ± 11.69

47.64 ± 9.53
1291.6 ± 258.3
1.02 ± 0.20
129.3 ± 25.9
17.70 ± 3.54

0.008
0.522
0.008
0.029
0.014

0.002
0.250
0.001
0.012
0.002

MUSCLE
Complex I
Complex II
Complex III
Complex II -III
Complex IV

108.1 ± 8.25
278.1 ± 16.42
3.43 ± 0.48
263.7 ± 28.53
38.63 ± 5.60

9.73 ± 4.25
215.8 ± 18.41
0.70 ± 0.18
157.6 ± 15.36
53.93 ± 8.76

0.008
0.522
0.036
1.00
0.412

0.015
0.093
0.025
0.070
0.434

Table 1. Results of electron transport chain assays of Complexes I - IV from muscle and liver from wild-type and
DGUOK rats.
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EPR Signal

Liver
W/T

Liver
DGUOK
[ (%)]a
CuA
47 ± 13
44 ± 15
[NS]c
Heme a
200 ± 50 100 ± 60
[-50]
High-spin heme
116 ± 7
71 ± 9
[-39]
N1b + N2
26 ± 5
16 ± 5
[-39]
FeS N3
17 ± 8
8±5
[-53]
FeS N4
41 ± 8
20 ± 6
[-51]
All Complex I FeS 84 ± 12
44 ± 9
[-49]
S3 + Acn
10.8 ± 1.6 15 ± 2
[+37]
FeS S1
27 ± 10
29 ± 13
[NS]
FeS S2
ND
ND
S1 + S2
27 ± 10
29 ± 13
[NS]
Rieske FeS
99 ± 11
98 ± 12
[NS]
Mn(II)
295 ± 27 588 ± 32
[+99]

Muscle
W/T

Muscle
DGUOK
[ (%)]
13 ± 1
[+45]
ND

Heartb

31 ± 1
[-30]
28.2 ± 0.2 7.4 ± 0.5
[-74]
16 ± 1
5.5 ± 0.7
[-61]
33 ± 1
14 ± 1
[-59]
77 ± 1
26 ± 1
[-66]
1.3 ± 0.1
3.8 ± 0.1
[+192]
15 ± 1
8±1

183  3

ND
15 ± 1

60 ± 5
76 ± 7

9±1
ND
44 ± 1

37 ± 1
32 ± 3

ND
8±1
[-48]
18 ± 1
[-51]
20 ± 2
[-35]

Bennett et al

NDd
200 ± 30

111  1
38  4
108  4
257  6
17  1
16 ± 5

238 ± 5
ND

Table 2. Fitting parameters for the EPR signals from spectra of liver and muscle tissue from wild-type and DGUOK rats.
The absolute intensities of each species (or group of species) are shown for wild-type and DGUOK, along with the
percentage differences between DGUOK and wild-type intensities in brackets.
Footnotes. (a) Calculated as {[(DGUOK signal) - (wild-type signal)]  (wild-type signal)}  100. (b) Wild-type and
DGUOK heart were indistinguishable. (c) Not significant. (d) None detected.
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Figure 1. Absolute mtDNA content in DGUOK rats. The mtDNA copy numbers for eight week old M1 and M2
DGUOK knockout rats compared with wild-type (SS) rats. The error bars indicate standard deviations for n = 6 (SS), n =
4 (M1) and n = 3 (M2).
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Figure 2: Skeletal muscle pathology in 11 month old WT and DGUOK rats. Quadriceps muscles from DGUOK rats
display little differences on H&E staining in comparison to WT littermates. In contrast, staining for COX and SDH
reveals numerous fibers in DGUOK rat muscle that are negative for both COX and SDH, whereas no such fibers were
evident in WT rat muscle. The bar at the bottom, right corresponds to 200 m.
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Figure 32. Respiratory chain complex expression in DGUOK rat muscle. Western blots of mitochondrial electron
transport chain complexes I-V and GAPDH from stripped membranes of quadriceps muscle from 11 month old wild-type
and DGUOK rats are shown in the top panel. The results of quantitation of the respiratory chain complex bands are shown
below, normalized for GAPDH expression. The error bars indicate standard deviations errors for n = 4.
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DGK activity (% of W/T)
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Figure 43. Electron transport chain functional assays of Complexes I - IV. The functional activities of
Complexes I - IV from liver and quadriceps muscle of DGUOK rat are shown, normalized for mitochondrial content (as
citrate synthase activity) and expressed as percentages of activities from wild-type. Detailed results are given in Table 1
(or S1).
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Figure 5. 12 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat
liver; B, DGUOK rat liver; C, wild-type rat quadriceps muscle; D, DGUOK rat quadriceps muscle; E, wild-type rat heart;
and F, DGUOK rat heart. In each case, the sample completely filled the part of the EPR tube that occupied the active
region of the resonator. A & B shown x 1, C & D are shown x 2, and E & F shown x 0.5. Spectra were recorded at 12 K,
2.5 mW power. The lower-case labels identify specific signals in the spectra: (a) high-spin axial ferriheme g; (b)
transferrin non-heme Fe(III); (c) the mI = 5/2 line at the low-field extremity of the six-line Mn(II) hyperfine pattern; (d)
overlapping signals from aconitase and S3 [3Fe4S] clusters; (e) overlapping g2 resonances from Complex I [2Fe2S] and
[4Fe4S] clusters; (f) resolved g3 resonances from N4 and N3 clusters; (g) high-spin catalase gx and gy lines; (h) low-spin
catalase resonances; (i) heme a g1; and (k) Rieske [2Fe2S] cluster g1 and g3 resonances.
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Figure 6. 40 K EPR spectra from wild-type and DGUOK rat tissue. The spectra are from samples of A, wild-type rat
liver (solid line) and DGUOK rat liver (dashed line); and B, wild-type rat quadriceps muscle (solid line) and DGUOK rat
muscle (dashed line). Spectra were recorded at 40 K, 2.5 mW power.
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Figure 7. Quantitative analysis of the 12 K EPR signals from wild-type and DGUOK rat tissues. Traces A, B, E, F, I
and J show the g' ~ 2 region of the EPR spectra of A, wild-type rat liver; B, DGUOK rat liver; E, wild-type rat
quadricepquadriceps muscle; F, DGUOK rat quadricepquadriceps muscle; I, wild-type rat heart; and J, DGUOK rat heart.
Trace C is the difference spectrum obtained by subtraction of A from B, and is shown multiplied by a factor of two;
likewise, G = 2(F - E) and K = 2(J - I). Trace D is a theoretical simulation of C generated by the subtraction of fits of A
and B to model spectra of the paramagnetic species likely to be observed in the mitochondrion. Fitting parameters are
presented in Table 2 (or S2). Similarly, trace H is a simulation of J from fits to E and F. No attempt was made to simulate
K, as no significant differences were observed between fits to I and J.
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Figure 8. Summary of EPR of DGUOK rat liver and muscle. A comparison of signal intensities is shown for some of
the respiratory complex redox centers in liver and muscle from the DGUOK and wild-type rat. The standard errors were
calculated from those of the fit parameters, presented in Table 2 (or S2).
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Table S1
In contrast to liver (n=5), mtDNA content in muscle tissue from 4 Wild Type (Dahl/SS) rats compared with 4
DGUOK M2 rats demonstrates no significant difference.

SOLEUS MUSCLE
GASTROCNEMIUS MUSCLE
TRICEP MUSCLE
DELTOID MUSCLE
LIVER

WILD TYPE RAT
1036
910
1270
1043
1981

DGUOK M2 RAT
710
571
418
1043
187
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0.72
0.31
0.25
0.81
0.0002

